[
      {
            "id": 1,
            "name": "Benzodiazepines",
            "learnItems":[
                  {
                        "title":"SAR Requirements",  
                        "name" : "Hover over the compound to learn about the SAR Characteristics",
                        "imagePath" : "slide-4a.PNG",
                        "compoundHotspots" : [
                              {
                                    "name": "Ring A",
                                    "y": 263,
                                    "x": 292,
                                    "size": 40,
                                    "color": "red",
                                    "text": "Pi-Pi stacking with BZR"
                              },
                              {
                                    "name": "Ring B",
                                    "y": 280,
                                    "x": 203,
                                    "size": 30,
                                    "color": "green",
                                    "text": "H-bond acceptor (O, N, S) or N-heterocycle required. 1,2 annelation (N-heterocycle) increases affinity for BZR"
                              },
                              {
                                    "name": "N1",
                                    "y": 209,
                                    "x": 266,
                                    "size": 30,
                                    "color": "blue",
                                    "text": "Methyl group preferred; bulky group decreases activity because it prevents binding to BZR"
                              },
                              {
                                    "name": "C7",
                                    "y": 317,
                                    "x": 154,
                                    "size": 30,
                                    "color": "orange",
                                    "text": "EWG increases activity"
                              },
                              {
                                    "name": "Ring C",
                                    "y": 411,
                                    "x": 288,
                                    "size": 30,
                                    "color": "deeppink",
                                    "text": "Hydrophobic interaction with BZR"
                              },
                              {
                                    "name": "C2",
                                    "y": 375,
                                    "x": 340,
                                    "size": 25,
                                    "color": "brown",
                                    "text": "F or Cl substitution reduces aromatic hydroxylation and improves half-life"
                              },
                              {
                                    "name": "C3",
                                    "y": 245,
                                    "x": 354,
                                    "size": 25,
                                    "color": "purple",
                                    "text": "OH group eliminates first pass metabolism as the hydroxyl acts as a “handle” for conjugation."
                              },
                              {
                                    "name": "C4",
                                    "y": 466,
                                    "x": 288,
                                    "size": 25,
                                    "color": "darkgoldenrod",
                                    "text": "steric repulsion occurs with para substituent"
                              }
                        ]
                  },
                  {
                        "title":"SAR Requirements",  
                        "name" : "Hover over the compound to learn about the SAR Characteristics",
                        "imagePath" : "slide-4b.PNG",
                        "compoundHotspots" : [
                              {
                                    "name": "Ring A",
                                    "y": 291,
                                    "x": 292,
                                    "size": 40,
                                    "color": "red",
                                    "text": "Pi-Pi stacking with BZR"
                              },
                              {
                                    "name": "Ring B",
                                    "y": 305,
                                    "x": 203,
                                    "size": 30,
                                    "color": "green",
                                    "text": "H-bond acceptor (O, N, S) or N-heterocycle required. 1,2 annelation (N-heterocycle) increases affinity for BZR"
                              },
                              {
                                    "name": "N1",
                                    "y": 241,
                                    "x": 266,
                                    "size": 30,
                                    "color": "blue",
                                    "text": "Methyl group preferred; bulky group decreases activity because it prevents binding to BZR"
                              },
                              {
                                    "name": "C7",
                                    "y": 345,
                                    "x": 159,
                                    "size": 30,
                                    "color": "orange",
                                    "text": "EWG increases activity"
                              },
                              {
                                    "name": "Ring C",
                                    "y": 440,
                                    "x": 291,
                                    "size": 30,
                                    "color": "deeppink",
                                    "text": "Hydrophobic interaction with BZR"
                              },
                              {
                                    "name": "C2",
                                    "y": 410,
                                    "x": 340,
                                    "size": 25,
                                    "color": "brown",
                                    "text": "F or Cl substitution reduces aromatic hydroxylation and improves half-life"
                              },
                              {
                                    "name": "C3",
                                    "y": 273,
                                    "x": 356,
                                    "size": 25,
                                    "color": "purple",
                                    "text": "OH group eliminates first pass metabolism as the hydroxyl acts as a “handle” for conjugation."
                              },
                              {
                                    "name": "C4",
                                    "y": 490,
                                    "x": 288,
                                    "size": 25,
                                    "color": "darkgoldenrod",
                                    "text": "steric repulsion occurs with para substituent"
                              }
                        ]
                  },
                  {
                        "title":"SAR Requirements",  
                        "name" : "Hover over Lorazepam to learn about the SAR Characteristics",
                        "imagePath" : "slide-5a.PNG",
                        "compoundHotspots" : [
                              {
                                    "name": "Ring A",
                                    "y": 227,
                                    "x": 209,
                                    "size": 30,
                                    "color": "red",
                                    "text": "Pi-Pi stacking with BZR"
                              },
                              {
                                    "name": "Ring B",
                                    "y": 158,
                                    "x": 291,
                                    "size": 30,
                                    "color": "green",
                                    "text": "H-bond acceptor (O, N, S) or N-heterocycle required. 1,2 annelation (N-heterocycle) increases affinity for BZR"
                              },
                              {
                                    "name": "N1",
                                    "y": 164,
                                    "x": 223,
                                    "size": 30,
                                    "color": "blue",
                                    "text": "Methyl group preferred; bulky group decreases activity because it prevents binding to BZR"
                              },
                              {
                                    "name": "C7",
                                    "y": 264,
                                    "x": 159,
                                    "size": 30,
                                    "color": "orange",
                                    "text": "EWG increases activity"
                              },
                              {
                                    "name": "Ring C",
                                    "y": 310,
                                    "x": 263,
                                    "size": 30,
                                    "color": "deeppink",
                                    "text": "Hydrophobic interaction with BZR"
                              },
                              {
                                    "name": "C3",
                                    "y": 202,
                                    "x": 335,
                                    "size": 25,
                                    "color": "purple",
                                    "text": "OH group eliminates first pass metabolism as the hydroxyl acts as a “handle” for conjugation."
                              },
                              {
                                    "name": "C2",
                                    "y": 279,
                                    "x": 319,
                                    "size": 25,
                                    "color": "brown",
                                    "text": "F or Cl substitution reduces aromatic hydroxylation and improves half-life"
                              }
                        ],
                        "colorLocationAssociations" : [
                              {"color": "red", "location": "Ring A", "description" : "Ring A: Pi-Pi stacking with BZR" },
                              {"color": "orange", "location": "C7", "description" : "C7: EWG increases activity" },
                              {"color": "green", "location": "Ring B", "description" : "Ring B:  H-bond acceptor (O, N, S) or N-heterocycle required 1,2 annelation (N-heterocycle) increases affinity for BZR" },
                              {"color": "blue", "location": "N1", "description" : "N1: methyl group preferred; bulky group decreases activity because it prevents binding to BZR" },
                              {"color": "purple", "location": "C3", "description" : "C3: OH group eliminates first pass metabolism as the hydroxyl acts as a “handle” for conjugation." },
                              {"color": "deeppink", "location": "Ring C", "description" : "Ring C: Hydrophobic interaction with BZR" },
                              {"color": "darkgoldenrod", "location": "C4", "description" : "C4: Steric repulsion occurs with para substituent " },
                              {"color": "teal", "location": "C2", "description" : "C2:  F or Cl substitution reduces aromatic hydroxylation and improves half-life" }
                        ]
                  },
                  {
                        "title":"SAR Requirements",
                        "name" : "Hover over Alprazolam to learn about the SAR Characteristics",
                        "imagePath" : "slide-5b.PNG",
                        "compoundHotspots" : [
                              {
                                    "name": "Ring A",
                                    "y": 276,
                                    "x": 229,
                                    "size": 50,
                                    "color": "red",
                                    "text": "Pi-Pi stacking with BZR"
                              },
                              {
                                    "name": "Ring B",
                                    "y": 197,
                                    "x": 303,
                                    "size": 50,
                                    "color": "green",
                                    "text": "H-bond acceptor (O, N, S) or N-heterocycle required. 1,2 annelation (N-heterocycle) increases affinity for BZR"
                              },
                              {
                                    "name": "N1",
                                    "y": 178,
                                    "x": 223,
                                    "size": 30,
                                    "color": "blue",
                                    "text": "Methyl group preferred; bulky group decreases activity because it prevents binding to BZR"
                              },
                              {
                                    "name": "C7",
                                    "y": 328,
                                    "x": 165,
                                    "size": 40,
                                    "color": "orange",
                                    "text": "EWG increases activity"
                              },
                              {
                                    "name": "Ring C",
                                    "y": 384,
                                    "x": 300,
                                    "size": 50,
                                    "color": "deeppink",
                                    "text": "Hydrophobic interaction with BZR"
                              }
                        ]
                  },
                  {
                        "title":"SAR Practice Problem",
                        "name" : "Activity Change",
                        "imagePath" : "slide7-transition.jpg",
                        "question" : "Would the following change to the compound increase, decrease, or have no effect upon activity?",
                        "options" : [
                              "Increase",
                              "Decrease",
                              "No Effect"
                        ],
                        "answer" : "Decrease",
                        "explanation" : "Addition of a bulky group at N1 prevents binding to the BZR; methyl group is preferred"
                  },
                  {
                        "title":"SAR Practice Problem",  
                        "name" : "Activity Change",
                        "imagePath" : "slide8.PNG",
                        "question" : "Would the following change to the compound increase, decrease, or have no effect upon activity?",
                        "options" : [
                              "Increase", 
                              "Decrease", 
                              "No Effect"
                        ],
                        "answer" : "Increase",
                        "explanation" : "Addition of Cl to position 2 reduces aromatic hydroxylation (phase one P450 metabolism) and increases half-life"
                  },
                  {
                        "title":"SAR Practice Problem",  
                        "name" : "Compare Compounds",
                        "imagePath" : "slide10.PNG",
                        "question" : "Which of these 3 compounds would be the best benzodiazepine for use as a hypnotic?",
                        "options" : [
                              "Compound 1", 
                              "Compound 2", 
                              "Compound 3"
                        ],
                        "answer" : "Compound 1",
                        "explanation" : "It already has the hydroxyl handle (position 3) so it is quickly metabolized to an inactive metabolite by conjugation; thus it has a short elimination half-life, which is ideal for hypnotics"
                  },
                  {
                        "title":"SAR Practice Problem",  
                        "name" : "Compare Compounds",
                        "imagePath" : "slide11.PNG",
                        "question" : "Which of these 3 compounds would be the best benzodiazepine for use as an anxiolytic?",
                        "options" : [
                              "Compound 1", 
                              "Compound 2", 
                              "Compound 3"
                        ],
                        "answer" : "Compound 2",
                        "explanation" : "The compound is slowly absorbed because it has a carboxylic acid that must be cleaved first (like a prodrug) and it is metabolized to an active metabolite; thus it has a long elimination half-life (40-50 hr), which is ideal for anxiolytics"
                  },
                  {
                        "title":"SAR Practice Problem",  
                        "name" : "Predict Metabolite Activity",
                        "imagePath" : "slide13.PNG",
                        "question" : "Predict whether the metabolites will be active or inactive for the compounds (2, 3) and Conjugated Products",
                        "options" : [ 
                              "Active, Active, Inactive",
                              "Active, Inactive, Inactive", 
                              "Inactive, Inactive, Active",
                              "Inactive, Active, Inactive"
                        ],
                        "answer" : "Active, Active, Inactive",
                        "explanation" : ""
                  },
                  {
                        "title":"SAR Practice Problem",  
                        "name" : "Predict Metabolite Activity",
                        "imagePath" : "slide14.PNG",
                        "question" : "Would compound 1 (temazepam) be an ideal hypnotic or anxiolytic? Predict whether the metabolites will be active or inactive for compound 2",
                        "options" : [
                              "Anxiolytic, Active",
                              "Anxiolytic, Inactive",
                              "Hypnotic, Inactive",
                              "Hypnotic, Active"
                        ],
                        "answer" : "Hypnotic, Inactive",
                        "explanation" : ""
                  },
                  {
                        "title":"SAR Practice Problem",  
                        "name" : "Predict Metabolite Activity",
                        "imagePath" : "slide15.PNG",
                        "question" : "Would compound 1 (triazolam) be an ideal hypnotic or anxiolytic? Predict whether the metabolites will be active or inactive for the compounds (2, 3) and Conjugated Products",
                        "options" : [
                              "Anxiolytic, Active, Inactive, Inactive",
                              "Anxiolytic, Inactive, Active, Inactive",
                              "Hypnotic, Inactive, Active, Inactive",
                              "Hypnotic, Active, Inactive, Inactive"
                        ],
                        "answer" : "Hypnotic, Inactive, Active, Inactive",
                        "explanation" : ""
                  }
            ], 
            "testItems":[
                  {
                        "title":"Side-Effects",  
                        "question" : "Benzodiazepines act at _______ receptor to increase _______ channel opening:",
                        "options" : [ 
                              "GABA, Ca2+",
                              "GABA, Na+",
                              "GABA, Cl-",
                              "glutamate, Ca2+",
                              "glutamate, Na+",
                              "glutamate, Cl-"
                        ],
                        "answer" : "GABA, Cl-"
                  },
                  {
                        "title":"Side-Effects",  
                        "question" : "Benzodiazepines will be affected by the inhibitors or activators of",
                        "options" : [
                              "CYP2B6", 
                              "CYP3A4", 
                              "CYP2C9",
                              "C3PO"
                        ],
                        "answer" : "CYP3A4"
                  },
                  {
                        "title":"Side-Effects",  
                        "question" : "Diazepam and ______ are useful to treat withdrawal from _______",
                        "options" : [
                              "clonazepam, nicotine", 
                              "clonazepam, alcohol", 
                              "triazolam, opioids",
                              "triazolam, nicotine",
                              "midazolam, alcohol",
                              "midazolam, opioids",
                              "lorazepam, nicotine",
                              "lorazepam, alcohol"
                        ],
                        "answer" : "lorazepam, alcohol"
                  },
                  {
                        "title":"Side-Effects",  
                        "question" : "Lorazepam, ______, and ______ are all used to treat status epilepticus",
                        "options" : [
                              "clonazepam, midazolam", 
                              "clonazepam, triazolam", 
                              "diazepam, clonazepam",
                              "diazepam, midazolam"
                        ],
                        "answer" : "diazepam, clonazepam"
                  },
                  {
                        "title":"Side-Effects",  
                        "question" : "Patient Smith has been prescribed a benzodiazepine and another medication for OCD. Smith feels excessively sleepy and has noticed her balance is off. Smith is probably taking diazepam and",
                        "options" : [
                              "bupropion",
                              "nortriptyline",
                              "fluoxetine"
                        ],
                        "answer" : "bupropion"
                  },
                  {
                        "title":"Contraindication",  
                        "question" : "This benzodiazepine is best suited for elderly individuals with liver damage:",
                        "options" : [
                              "Lorazepam", 
                              "Diazepam", 
                              "Clonazepam"
                        ],
                        "answer" : "Lorazepam"
                  },
                  {
                        "title":"Side-Effects",  
                        "question" : "An individual who takes benzodiazepine usually develops tolerance to",
                        "options" : [
                              "sedative effects", 
                              "anxiolytic effects", 
                              "anesthetic effects"
                        ],
                        "answer" : "sedative effects"
                  },
                  {
                        "title":"Side-Effects",  
                        "question" : "When a benzodiazepine is taken for sleep, benzodiazepine's long elimination half life can cause:",
                        "options" : [
                              "headache", 
                              "insomnia", 
                              "grogginess",
                              "amnesia"
                        ],
                        "answer" : "grogginess"
                  },
                  {
                        "title":"Side-Effects",  
                        "question" : "A serious and unusual side effect of a benzodiazepine is",
                        "options" : [
                              "Induction of P450s", 
                              "G6P deficiency", 
                              "amnesia"
                        ],
                        "answer" : "amnesia"
                  },
                  {
                        "title":"Side-Effects",  
                        "question" : "An individual who takes benzodiazepine rarely develops tolerance to",
                        "options" : [
                              "sedative effects", 
                              "anxiolytic effects", 
                              "anesthetic effects"
                        ],
                        "answer" : "anxiolytic effects"
                  }
            ],
            "reviewItems":[
                  {
                        "title": "Drugs",  
                        "sections" : [
                              {"title": "Diazepam", "imagePath": "diazepam.PNG" },
                              {"title": "Lorazepam", "imagePath": "lorazepam.PNG" }, 
                              {"title": "Temazepam", "imagePath": "temazepam.PNG" },
                              {"title": "Triazolam", "imagePath": "triazolam.PNG" },
                              {"title": "Midazolam", "imagePath": "midazolam.PNG" }
                        ]
                  },
                  {
                        "title": "SAR Characteristics",  
                        "sections" : [
                              {"title": "", "content": "" },
                              {"title": "", "content": "" }, 
                              {"title": "", "content": "" },
                              {"title": "", "content": "" },
                              {"title": "", "content": "" },
                              {"title": "", "content": "" },
                              {"title": "", "content": "" },
                              {"title": "", "content": "" }
                        ]
                  },
                  {
                        "title": "Pharmokinetic",  
                        "sections" : [
                              {"title": "Absorption", "content": "" },
                              {"title": "Distribution", "content": "" }, 
                              {"title": "Metabolism", "content": "" },
                              {"title": "Excretion", "content": ""  }
                        ]
                  },
                  {
                        "title": "Action",  
                        "sections" : [
                              {"title": "MOA", "imagePath": "moa.PNG" },
                              {"title": "Mechanism of Action", "content": "" },
                              {"title": "Pharmacological Action", "content": "" }
                        ]
                  },
                  {
                        "title": "Side-Effects",  
                        "sections" : [
                              {"title": "Side-Effects", "content": "" }
                        ]
                  },
                  {
                        "title": "Uses",  
                        "sections" : [
                              {"title": "Uses", "content": "" }
                        ]
                  },
                  {
                        "title": "Notes",  
                        "sections" : [
                              {"title": "Notes", "content": "" }
                        ]
                  }
            ],
            "exampleReview":[
                  {
                        "title": "Drugs",  
                        "sections" : [
                              {"title": "Diazepam (Long Acting)", "imagePath": "diazepam.PNG" },
                              {"title": "Lorazepam (Intermediate Acting)", "imagePath": "lorazepam.PNG" }, 
                              {"title": "Temazepam (Intermediate Acting)", "imagePath": "temazepam.PNG" },
                              {"title": "Triazolam (Short Acting)", "imagePath": "triazolam.PNG" },
                              {"title": "Midazolam (Short Acting)", "imagePath": "midazolam.PNG" }
                        ]
                  },
                  {
                        "title": "SAR Characteristics",  
                        "sections" : [
                              {"title": "Ring A", "content": "Pi-Pi stacking with BZR" },
                              {"title": "C7", "content": "EWG increases activity" }, 
                              {"title": "Ring B", "content": "H-bond acceptor (O, N, S) or N-heterocycle required 1,2 annelation (N-heterocycle) increases affinity for BZR" },
                              {"title": "N1", "content": "methyl group preferred; bulky group decreases activity because it prevents binding to BZR" },
                              {"title": "C3", "content": "OH group eliminates first pass metabolism as the hydroxyl acts as a “handle” for conjugation." },
                              {"title": "Ring C", "content": "Hydrophobic interaction with BZR" },
                              {"title": "C4", "content": "Steric repulsion occurs with para substituent" },
                              {"title": "C2", "content": "F or Cl substitution reduces aromatic hydroxylation and improves half-life" }
                        ]
                  },
                  {
                        "title": "Pharmokinetic",  
                        "sections" : [
                              {"title": "Absorption", "content": "When taken orally, most BZD show rapid and complete absorption from GI tract" },
                              {"title": "Distribution", "content": "-Increase lipophilicity = Increase rate of CNS distribution. -Cross BBB by passive diffusion." }, 
                              {"title": "Metabolism", "content": "-Do NOT induce metabolism of other drugs. -Liver metabolized to active compounds (except lorazepam)" },
                              {"title": "Excretion", "content": "By kidneys" },
                              {"title": "Duration of Action", "content": "[Short Acting]: 1.5-5 hours, Not converted into active intermediates. [Intermediate Acting]: 8-20 hours. [Long Acting]: 30-60 hours, Converted into active intermediates." }
                        ]
                  },
                  {
                        "title": "Action",  
                        "sections" : [
                              {"title": "MOA", "imagePath": "moa.PNG" },
                              {"title": "Mechanism of Action", "content": "-Potentiates GABA by binding to allosteric site on receptor. Increase the frequency of Cl- channel opening. -Enhancement of GABA activity slows nerve impulses throughout the body, GABA produces calming effect in the brain." },
                              {"title": "Pharmacological Action", "content": "-Sedation (decrease latency and REM). -Reduction in muscle tone. -Tolerance develops after 1-2 weeks of use. -Reduction in anxiety." }
                        ]
                  },
                  {
                        "title": "Side-Effects",  
                        "sections" : [
                              {"title": "Side-Effects", "content": "Drowsiness, Fatigue, Amnesia, Ataxia" }
                        ]
                  },
                  {
                        "title": "Uses",  
                        "sections" : [
                              {"title": "Uses", "content": "Anti-Epileptic (diazepam, lorazepam), Insomnia (temazepam, triazolam), Anti-anxiety (diazepam, lorazepam), Muscle spasms (diazepam), Anesthesia (diazepam, lorazepam, midazolam). *Duration of Action determines therapeutic use." }
                        ]
                  },
                  {
                        "title": "Notes",  
                        "sections" : [
                              {"title": "Notes", "content": "-Duration of action and elimination half life are NOT the same. -BZD increase frequency of Cl- channel opening. -GABA must be present for BZD to have effect. -Flumazenil = BZD receptor antagonist for treatment of acute overdose." }
                        ]
                  }
            ]
      },
      {
            "id": 2,
            "name": "Barbiturates",
            "learnItems":[
                  {
                        "title":"SAR Requirements",  
                        "name" : "Hover over the compound to learn about the SAR Characteristics",
                        "imagePath" : "slide26.PNG",
                        "compoundHotspots" : [
                              {
                                    "name": "N1",
                                    "y": 234,
                                    "x": 191,
                                    "size": 40,
                                    "color": "red",
                                    "text": "Must be a nitrogen and unsubstitued if N3 is substituted. Carbon group substitution will increase lipophilicity and more rapid onset of action."
                              },
                              {
                                    "name": "N3",
                                    "y": 234,
                                    "x": 307,
                                    "size": 40,
                                    "color": "orange",
                                    "text": "Must be a nitrogen and unsubstituted if N1 is substituted. Carbon group substitution will increase lipophilicity and more rapid onset of action."
                              },
                              {
                                    "name": "C2",
                                    "y": 164,
                                    "x": 250,
                                    "size": 40,
                                    "color": "green",
                                    "text": "Changing C=O → C=S increases lipophilicity and more rapid onset of action"
                              },
                              {
                                    "name": "C4 & C6",
                                    "y": 311,
                                    "x": 334,
                                    "size": 40,
                                    "color": "blue",
                                    "text": "Must contain C=O"
                              },
                              {
                                    "name": "C4 & C6",
                                    "y": 311,
                                    "x": 163,
                                    "size": 40,
                                    "color": "blue",
                                    "text": "Must contain C=O"
                              },
                              {
                                    "name": "R1 & R2",
                                    "y": 365,
                                    "x": 253,
                                    "size": 55,
                                    "color": "deeppink",
                                    "text": "bulky carbon groups increases lipophilicity and more rapid onset of action"
                              },
                              {
                                    "name": "5,5",
                                    "y": 300,
                                    "x": 250,
                                    "size": 30,
                                    "color": "goldenrod",
                                    "text": "disubstitution required for activity"
                              }
                        ]
                  },
                  {
                        "title":"SAR Requirements",  
                        "name" : "Disubstitution Required for Activity",
                        "imagePath" : "slide27a.PNG",
                        "colorLocationAssociations" : [
                              {"color": "black", "location": "N1", "description" : "Barbiturates can undergo enol-keto tautomerization, which gives them near neutral pkas (7.4). Less than 50% gets ionized, so good balance of solubility and CNS penetration." }
                        ]
                  },
                  {
                        "title":"SAR Requirements",  
                        "name" : "Disubstitution Required for Activity",
                        "imagePath" : "slide27b.PNG",
                        "colorLocationAssociations" : [
                              {"color": "black", "location": "N1", "description" : "Without any substitution at position 5, the acidic hydrogen gets deprotonated. Resonance stabilization leads to lower pka (4) and 99% ionization occurs, so unable to penetrate the CNS." }
                        ]
                  },
                  {
                        "title":"SAR Requirements",  
                        "name" : "Hover over Phenobarbital to learn about the SAR Characteristics",
                        "imagePath" : "slide28a.PNG",
                        "compoundHotspots" : [
                              {
                                    "name": "N1",
                                    "y": 218,
                                    "x": 180,
                                    "size": 40,
                                    "color": "red",
                                    "text": "Must be a nitrogen and unsubstitued if N3 is substituted. Carbon group substitution will increase lipophilicity and more rapid onset of action."
                              },
                              {
                                    "name": "N3",
                                    "y": 218,
                                    "x": 302,
                                    "size": 40,
                                    "color": "orange",
                                    "text": "Must be a nitrogen and unsubstituted if N1 is substituted. Carbon group substitution will increase lipophilicity and more rapid onset of action."
                              },
                              {
                                    "name": "C2",
                                    "y": 162,
                                    "x": 238,
                                    "size": 40,
                                    "color": "green",
                                    "text": "Changing C=O → C=S increases lipophilicity and more rapid onset of action"
                              },
                              {
                                    "name": "C4 & C6",
                                    "y": 294,
                                    "x": 162,
                                    "size": 40,
                                    "color": "blue",
                                    "text": "Must contain C=O"
                              },
                              {
                                    "name": "C4 & C6",
                                    "y": 294,
                                    "x": 314,
                                    "size": 40,
                                    "color": "blue",
                                    "text": "Must contain C=O"
                              },
                              {
                                    "name": "R1 & R2",
                                    "y": 385,
                                    "x": 262,
                                    "size": 80,
                                    "color": "deeppink",
                                    "text": "bulky carbon groups increases lipophilicity and more rapid onset of action"
                              },
                              {
                                    "name": "5,5",
                                    "y": 288,
                                    "x": 238,
                                    "size": 30,
                                    "color": "goldenrod",
                                    "text": "disubstitution required for activity"
                              }
                        ]
                  },
                  {
                        "title":"SAR Requirements",  
                        "name" : "Hover over Thiopental to learn about the SAR Characteristics",
                        "imagePath" : "slide28b.PNG",
                        "compoundHotspots" : [
                              {
                                    "name": "N1",
                                    "y": 210,
                                    "x": 174,
                                    "size": 40,
                                    "color": "red",
                                    "text": "Must be a nitrogen and unsubstitued if N3 is substituted. Carbon group substitution will increase lipophilicity and more rapid onset of action."
                              },
                              {
                                    "name": "N3",
                                    "y": 210,
                                    "x": 274,
                                    "size": 40,
                                    "color": "orange",
                                    "text": "Must be a nitrogen and unsubstituted if N1 is substituted. Carbon group substitution will increase lipophilicity and more rapid onset of action."
                              },
                              {
                                    "name": "C2",
                                    "y": 160,
                                    "x": 222,
                                    "size": 40,
                                    "color": "green",
                                    "text": "Changing C=O → C=S increases lipophilicity and more rapid onset of action"
                              },
                              {
                                    "name": "C4 & C6",
                                    "y": 270,
                                    "x": 152,
                                    "size": 40,
                                    "color": "blue",
                                    "text": "Must contain C=O"
                              },
                              {
                                    "name": "C4 & C6",
                                    "y": 270,
                                    "x": 294,
                                    "size": 40,
                                    "color": "blue",
                                    "text": "Must contain C=O"
                              },
                              {
                                    "name": "R1 & R2",
                                    "y": 364,
                                    "x": 234,
                                    "size": 80,
                                    "color": "deeppink",
                                    "text": "bulky carbon groups increases lipophilicity and more rapid onset of action"
                              },
                              {
                                    "name": "5,5",
                                    "y": 268,
                                    "x": 223,
                                    "size": 30,
                                    "color": "goldenrod",
                                    "text": "disubstitution required for activity"
                              }
                        ],
                        "colorLocationAssociations" : [
                              {"color": "red", "location": "N1", "description" : "N1: Must be a nitrogen and unsubstitued if N3 is substituted. Carbon group substitution will increase lipophilicity and more rapid onset of action." },
                              {"color": "orange", "location": "N3", "description" : "N3: must be a nitrogen and unsubstituted if N1 is substituted. Carbon group substitution will increase lipophilicity and more rapid onset of action " },
                              {"color": "green", "location": "C2", "description" : "C2: changing C=O → C=S increases lipophilicity and more rapid onset of action" },
                              {"color": "blue", "location": "C4 & C6", "description" : "C4 & C6: must contain C=O" },
                              {"color": "deeppink", "location": "R1 & R2", "description" : "R1 & R2: bulky carbon groups increases lipophilicity and more rapid onset of action " }
                        ]
                  },
                  {
                        "title":"SAR Practice Problem",  
                        "name" : "Activity Change",
                        "imagePath" : "slide30.PNG",
                        "question" : "Would the following change to the compound increase, decrease, or have no effect upon activity?",
                        "options" : [
                              "Increase", 
                              "Decrease", 
                              "No Effect"
                        ],
                        "answer" : "Decrease",
                        "explanation" : "Changing C=S to C=O decreases lipophilicity and onset of action"
                  },
                  {
                        "title":"SAR Practice Problem",  
                        "name" : "Activity Change",
                        "imagePath" : "slide31.PNG",
                        "question" : "Would the following change to the compound increase, decrease, or have no effect upon activity?",
                        "options" : [
                              "Increase", 
                              "Decrease", 
                              "No Effect"
                        ],
                        "answer" : "Increase",
                        "explanation" : "5,5- disubstitution needed for activity in order for CNS penetration"
                  },
                  {
                        "title":"SAR Practice Problem",  
                        "name" : "Compare Compounds",
                        "imagePath" : "slide33.PNG",
                        "question" : "Which of these 3 compounds would be a CNS active barbiturate?",
                        "options" : [
                              "Compound 1", 
                              "Compound 2", 
                              "Compound 3"
                        ],
                        "answer" : "Compound 3",
                        "explanation" : "5,5- disubstitution and weak acid (N1 or N3 must be unsubstituted) are required for activity in order for CNS penetration"
                  }
            ],
            "testItems":[
                  {
                        "title":"Mechanism of Action",  
                        "question" : "Higher doses of barbiturates bind these receptors in the cerebellum",
                        "options" : [
                              "GABAa", 
                              "GABAb", 
                              "glutamate"
                        ],
                        "answer" : "GABAa"
                  },
                  {
                        "title":"Mechanism of Action",  
                        "question" : "The long half life of barbiturates causes this effect",
                        "options" : [
                              "hangover", 
                              "rebound"
                        ],
                        "answer" : "hangover"
                  },
                  {
                        "title":"Mechanism of Action",  
                        "question" : "The short half life or abrupt discontinuation of barbiturates causes this effect",
                        "options" : [
                              "hangover", 
                              "rebound"
                        ],
                        "answer" : "rebound"
                  },
                  {
                        "title":"Mechanism of Action",  
                        "question" : "Higher doses of barbiturates bind [ans] receptors in the cerebellum causing the side effect of",
                        "options" : [
                              "Ataxia", 
                              "amnesia", 
                              "sedation"
                        ],
                        "answer" : "sedation"
                  }
            ], 
            "reviewItems":[
                  {
                        "title": "Drugs",  
                        "sections" : [
                              {"title": "Phenobarbital (Long Acting)", "imagePath": "phenobarbital.PNG" },
                              {"title": "Butabarbital (Intermediate Acting)", "imagePath": "butabarbital.PNG" }, 
                              {"title": "Pentobarbital (Short Acting)", "imagePath": "pentobarbital.PNG" },
                              {"title": "Secobarbital (Short Acting)", "imagePath": "secobarbital.PNG" }
                        ]
                  },
                  {
                        "title": "SAR Characteristics",  
                        "sections" : [
                              {"title": "", "content": "" },
                              {"title": "", "content": "" }, 
                              {"title": "", "content": "" },
                              {"title": "", "content": "" },
                              {"title": "", "content": "" },
                              {"title": "", "content": "" }
                        ]
                  },
                  {
                        "title": "Pharmokinetic",  
                        "sections" : [
                              {"title": "Absorption", "content": "" },
                              {"title": "Distribution", "content": "" }, 
                              {"title": "Metabolism", "content": "" },
                              {"title": "Excretion", "content": ""  }
                        ]
                  },
                  {
                        "title": "Action",  
                        "sections" : [
                              {"title": "Mechanism of Action", "imagePath": "moa-barbiturates.PNG" },
                              {"title": "MOA Explanation", "content": "" },
                              {"title": "Pharmacological Action", "content": "" }
                        ]
                  },
                  {
                        "title": "Side-Effects",  
                        "sections" : [
                              {"title": "Side-Effects", "content": "" }
                        ]
                  },
                  {
                        "title": "Uses",  
                        "sections" : [
                              {"title": "Uses", "content": "" }
                        ]
                  },
                  {
                        "title": "Reason for Limited Use",  
                        "sections" : [
                              {"title": "Notes", "content": "" }
                        ]
                  }
            ],
            "exampleReview":[
                  {
                        "title": "Drugs",  
                        "sections" : [
                              {"title": "Phenobarbital (Long Acting)", "imagePath": "phenobarbital.PNG" },
                              {"title": "Butabarbital (Intermediate Acting)", "imagePath": "butabarbital.PNG" }, 
                              {"title": "Pentobarbital (Short Acting)", "imagePath": "pentobarbital.PNG" },
                              {"title": "Secobarbital (Short Acting)", "imagePath": "secobarbital.PNG" }
                        ]
                  },
                  {
                        "title": "SAR Characteristics",  
                        "sections" : [
                              {"title": "N1", "content": "Must be a nitrogen and unsubstitued if N3 is substituted. Carbon group substitution will increase lipophilicity and more rapid onset of action." },
                              {"title": "N3", "content": "Must be a nitrogen and unsubstituted if N1 is substituted. Carbon group substitution will increase lipophilicity and more rapid onset of action." }, 
                              {"title": "C2", "content": "Changing C=O → C=S increases lipophilicity and more rapid onset of action" },
                              {"title": "C4 & C6", "content": "Must contain C=O" },
                              {"title": "R1 & R2", "content": "bulky carbon groups increases lipophilicity and more rapid onset of action" },
                              {"title": "C5", "content": "Must be disubstituted alkyl groups to be active in the CNS" }
                        ]
                  },
                  {
                        "title": "Pharmokinetic",  
                        "sections" : [
                              {"title": "Absorption", "content": "IV and Oral" },
                              {"title": "Distribution", "content": "Increases lipid solubility = quicker entry into CNS. Barbiturates redistribute from brain to muscles and fat tissue." }, 
                              {"title": "Metabolism", "content": "Metabolized in the liver" },
                              {"title": "Excretion", "content": "Excreted in urine by kidney"  }
                        ]
                  },
                  {
                        "title": "Action",  
                        "sections" : [
                              {"title": "Mechanism of Action", "imagePath": "moa-barbiturates.PNG" },
                              {"title": "MOA Explanation", "content": "Prolong GABA activity. Increase duration of Cl- channel opening. Also blocks the AMPA- receptor which is sensitive to glutamate, the excitatory transmitter. Blocking this action increases the duration of receptor response to GABA and extends the depressed condition of the cell." },
                              {"title": "Pharmacological Action", "content": "[CNS Depression]: Sedation at low doses. Hypnosis followed by anesthesia at high doses. [Respiratory Depression]: Suppress hypoxic and chemoreceptor response to C02 -> Can lead to death." }
                        ]
                  },
                  {
                        "title": "Side-Effects",  
                        "sections" : [
                              {"title": "Side-Effects", "content": "Alcohol like symptoms: Impaired motor control (ataxia), dizziness, slower breathing and heart rate. Enzyme induction (CYP450). Potential for addiction." }
                        ]
                  },
                  {
                        "title": "Uses",  
                        "sections" : [
                              {"title": "Uses", "content": "NOT used as sedative or hypnotic. Anesthetic: Ultra short acting (thiopental). Anti-seizure: Long acting (phenobarbital)." }
                        ]
                  },
                  {
                        "title": "Reason for Limited Use",  
                        "sections" : [
                              {"title": "Notes", "content": "Physical dependence, Severe withdrawal symptoms, low toxicity threshold, tolerance develops." }
                        ]
                  }
            ]
      },
      {
            "id": 3,
            "name": "Z-Drugs",
             "learnItems":[
                  {
                        "title":"Useful Structures",  
                        "name" : "Zaleplon",
                        "imagePath" : "zaleplon-useful.PNG",
                        "colorLocationAssociations" : [
                              {"color": "black", "location": "none", "description" : "Circled parts of each structure are helpful to associate with the compounds. There are no SAR Requirements for Z-Drugs" }
                        ]
                  },
                  {
                        "title":"Useful Structures",  
                        "name" : "Eszopiclone",
                        "imagePath" : "eszopiclone-useful.PNG",
                        "colorLocationAssociations" : [
                              {"color": "black", "location": "none", "description" : "Circled parts of each structure are helpful to associate with the compounds. There are no SAR Requirements for Z-Drugs" }
                        ]
                  },
                  {
                        "title":"Useful Structures",  
                        "name" : "Zolpidem",
                        "imagePath" : "zolpidem-useful.PNG",
                        "colorLocationAssociations" : [
                              {"color": "black", "location": "none", "description" : "Circled parts of each structure are helpful to associate with the compounds. There are no SAR Requirements for Z-Drugs" }
                        ]
                  },
                  {
                        "title":"Practice Problem",  
                        "name" : "Compare Compounds",
                        "imagePath" : "slide44.PNG",
                        "question" : "Trissa is 30-year old female suffering from anxiety and insomnia. What one compound would be best to treat both her anxiety and insomnia?",
                        "options" : [
                              "Compound 1", 
                              "Compound 2", 
                              "Compound 3"
                        ],
                        "answer" : "Compound 2",
                        "explanation" : "Benzodiazepine (Compound 2)"
                  },
                  {
                        "title":"Practice Problem",  
                        "name" : "Compare Compounds",
                        "imagePath" : "slide45.PNG",
                        "question" : "Sakiya is 24-year old female suffering from anxiety and insomnia. Sakiya’s boyfriend takes one of these hypnotics for insomnia and it helps keep him asleep with no hangover effects in the morning. LM decides to take one of his pills, but in the morning she is still sleepy. Which of these compounds did she take and why is she still experiencing effects in the morning?",
                        "options" : [
                              "Compound 1", 
                              "Compound 2", 
                              "Compound 3"
                        ],
                        "answer" : "Compound 1",
                        "explanation" : "Zolpidem (Compound 1); women metabolize slower"
                  },
                  {
                        "title":"Practice Problem",  
                        "name" : "Compare Compounds",
                        "imagePath" : "slide46.PNG",
                        "question" : "Lance is 27-year old female suffering from anxiety and insomnia. Unfortunately, Lance has had abuse disorders in the past. Which of these compounds would be safest to use to treat her insomnia?",
                        "options" : [
                              "Compound 1", 
                              "Compound 2", 
                              "Compound 3"
                        ],
                        "answer" : "Compound 3",
                        "explanation" : "Ramelteon (Compound 3); not a scheduled drug"
                  }
            ],
            "testItems":[
                  {
                        "title":"Mechanism of Action",  
                        "question" : "Eszopiclone binds to this receptor",
                        "options" : [
                              "barbiturate", 
                              "benzodiazepine", 
                              "dopamine"
                        ],
                        "answer" : "benzodiazepine"
                  },
                  {
                        "title":"Mechanism of Action",  
                        "question" : "Normal circadian rhythm is re-established by a drug acting at this receptor",
                        "options" : [
                              "dopamine", 
                              "serotonin", 
                              "melatonin"
                        ],
                        "answer" : "melatonin"
                  },
                  {
                        "title":"Mechanism of Action",  
                        "question" : "Eszopiclone binds to the benzodiazepine receptor and potentiates",
                        "options" : [
                              "GABA", 
                              "Glutamate", 
                              "dopamine"
                        ],
                        "answer" : "GABA"
                  },
                  {
                        "title":"Side-Effects",  
                        "question" : "Normal circadian rhythm is re-established at the melatonin receptor when this drug acts upon it",
                        "options" : [
                              "zolpidem", 
                              "mirtazapine", 
                              "ramelteon "
                        ],
                        "answer" : "ramelteon"
                  },
                  {
                        "title":"Side-Effects",  
                        "question" : "This drug has the longest half-life",
                        "options" : [
                              "Zolpidem", 
                              "Eszopiclone", 
                              "Ramelteon"
                        ],
                        "answer" : "Eszopiclone"
                  },
                  {
                        "title":"Side-Effects",  
                        "question" : "This drug has the longest potency",
                        "options" : [
                              "Zolpidem", 
                              "Eszopiclone", 
                              "Ramelteon"
                        ],
                        "answer" : "Zolpidem"
                  },
                  {
                        "title":"Side-Effects",  
                        "question" : "This drug is used to induce sleep",
                        "options" : [
                              "zolpidem", 
                              "zaleplon", 
                              "eszopiclone"
                        ],
                        "answer" : "zolpidem"
                  },
                  {
                        "title":"Side-Effects",  
                        "question" : "Zolpidem is metabolized slower by ",
                        "options" : [
                              "Men", 
                              "Women"
                        ],
                        "answer" : "Women"
                  },
                  {
                        "title":"Side-Effects",  
                        "question" : "John Smith is waking up regularly in the middle of the night. A good therapy for him would be",
                        "options" : [
                              "zolpidem",
                              "eszopiclone", 
                              "zaleplon"
                        ],
                        "answer" : "zaleplon"
                  },
                  {
                        "title":"Side-Effects",  
                        "question" : "Both the a1 and a1 benzodiazepine receptor is acted upon by ",
                        "options" : [
                              "eszopiclone", 
                              "zaleplon", 
                              "zolpidem "
                        ],
                        "answer" : "eszopiclone"
                  },
                  {
                        "title":"Side-Effects",  
                        "question" : "Z-drugs primarily cause",
                        "options" : [
                              "sedation", 
                              "amnesia", 
                              "anxiety relief"
                        ],
                        "answer" : "sedation"
                  },
                  {
                        "title":"Side-Effects",  
                        "question" : "Z-drugs bind primarily to this receptor",
                        "options" : [
                              "GABA", 
                              "benzodiazepine", 
                              "barbiturate "
                        ],
                        "answer" : "benzodiazepine"
                  },
                  {
                        "title":"Side-Effects",  
                        "question" : "Z-drugs bind primarily to benzodiazepine's subunit receptor:",
                        "options" : [
                              "benzodiazepine", 
                              "alpha1", 
                              "alpha2",
                              "beta"
                        ],
                        "answer" : "alpha1"
                  },
                  {
                        "title":"Side-Effects",  
                        "question" : "Z drugs are not effective antianxiety drugs because they bind primarily to the alpha1 subunit of benzodiazepine not the subunit:",
                        "options" : [
                              "benzodiazepine", 
                              "alpha1", 
                              "alpha2",
                              "beta"
                        ],
                        "answer" : "alpha2"
                  }
            ], 
            "reviewItems":[
                  {
                        "title": "Drugs",  
                        "sections" : [
                              {"title": "Zolpidem", "imagePath": "zolpidem.PNG" },
                              {"title": "Zaleplon", "imagePath": "zaleplon.PNG" }, 
                              {"title": "Eszopiclone", "imagePath": "eszopiclone.PNG" }
                        ]
                  },
                  {
                        "title": "Zolpidem",  
                        "sections" : [
                              {"title": "Key Characteristics", "content": "" },
                              {"title": "Key Pharmacokinetic", "content": "" }, 
                              {"title": "Action/Effect", "content": "" },
                              {"title": "Side Effects", "content": "" }
                        ]
                  },
                  {
                        "title": "Zaleplon",  
                        "sections" : [
                              {"title": "Key Characteristics", "content": "" },
                              {"title": "Key Pharmacokinetic", "content": "" }, 
                              {"title": "Action/Effect", "content": "" },
                              {"title": "Side Effects", "content": "" }
                        ]
                  },
                  {
                        "title": "Eszopiclone",  
                        "sections" : [
                              {"title": "Key Characteristics", "content": "" },
                              {"title": "Key Pharmacokinetic", "content": "" }, 
                              {"title": "Action/Effect", "content": "" },
                              {"title": "Side Effects", "content": "" }
                        ]
                  }
                  
            ],
            "exampleReview":[
                  {
                        "title": "Drugs",  
                        "sections" : [
                              {"title": "Zolpidem", "imagePath": "zolpidem.PNG" },
                              {"title": "Zaleplon", "imagePath": "zaleplon.PNG" }, 
                              {"title": "Eszopiclone", "imagePath": "eszopiclone.PNG" }
                        ]
                  },
                  {
                        "title": "Zolpidem",  
                        "sections" : [
                              {"title": "Key Characteristics", "content": "Women metabolize slower. Used to treat insomnia." },
                              {"title": "Key Pharmacokinetic", "content": "Rapidly absorbed in GI tract. Rapid onset and short elimination T1/2 (2-3 hours). Metabolism: Hepatic oxidation by CYP450." }, 
                              {"title": "Action/Effect", "content": "Selective for GABA-A alpha-1 subunit. Sedative." },
                              {"title": "Side Effects", "content": "Nightmares, agitation, headache, GI upset, dizziness, drowsiness." }
                        ]
                  },
                  {
                        "title": "Zaleplon",  
                        "sections" : [
                              {"title": "Key Characteristics", "content": "Used to treat insomnia." },
                              {"title": "Key Pharmacokinetic", "content": "Fewer residual effect on psychomotor and cognitive functions. Rapid elimination and T1/2 of 1 hour = Good to tak in the middle of night. Metabolism: CYP450." }, 
                              {"title": "Action/Effect", "content": "Selective for GABA-A alpha-1 subunit. Sedative." },
                              {"title": "Side Effects", "content": "Dizziness, Drowsiness, Lack of coordination." }
                        ]
                  },
                  {
                        "title": "Eszopiclone",  
                        "sections" : [
                              {"title": "Key Characteristics", "content": "Longest T1/2. Used for chronic insomnia." },
                              {"title": "Key Pharmacokinetic", "content": "Elimination half life ~6 hours. Metabolism: oxidation and demethylation via CYP450. Rapidly absorbed." }, 
                              {"title": "Action/Effect", "content": "Acts at several GABA-A subunits, including alpha-1 and alpha-2 subunit. Sedative and Anxiolytic." },
                              {"title": "Side Effects", "content": "Anxiety, dry mount, headache, peripheral edema, somnolence, unpleasant taste." }
                        ]
                  }
                  
            ]
      },
      {
            "id": 4,
            "name": "Anticonvulsants",
            "learnItems":[
                  {
                        "title":"SAR Trends",  
                        "name" : "Hover over Phenobarbital (barbiturate) to learn about the SAR Trends",
                        "imagePath" : "phenobarbital-sar.PNG",
                        "compoundHotspots" : [
                              {
                                    "name": "Phenobarbital Ureide",
                                    "y": 214,
                                    "x": 300,
                                    "size": 65,
                                    "color": "green",
                                    "text": "Phenobarbital's Ureide Common Scaffold"
                              }
                        ]
                  },
                  {
                        "title":"SAR Trends",  
                        "name" : "Hover over Ethosuximide (succinimide) to learn about the SAR Trends",
                        "imagePath" : "ethosuximide-sar.PNG",
                        "compoundHotspots" : [
                              {
                                    "name": "Ethosuximide Ureide",
                                    "y": 300,
                                    "x": 250,
                                    "size": 50,
                                    "color": "green",
                                    "text": "Ethosuximide's Ureide Common Scaffold"
                              }
                        ]
                  },
                  {
                        "title":"SAR Trends",  
                        "name" : "Hover over Phenytoin (hydantion) to learn about the SAR Trends",
                        "imagePath" : "phenytoin-sar.PNG",
                        "compoundHotspots" : [
                              {
                                    "name": "Phenytoin Ureide",
                                    "y": 286,
                                    "x": 270,
                                    "size": 50,
                                    "color": "green",
                                    "text": "Phenytoin's Ureide Common Scaffold"
                              }
                        ]
                  },
                  {
                        "title":"SAR Trends",  
                        "name" : "Hover over Fosphenytoin (hydantion) to learn about the SAR Trends",
                        "imagePath" : "fosphenytoin-sar.PNG",
                        "compoundHotspots" : [
                              {
                                    "name": "Fosphenytoin Ureide",
                                    "y": 250,
                                    "x": 255,
                                    "size": 40,
                                    "color": "green",
                                    "text": "Fosphenytoin's Ureide Common Scaffold"
                              }
                        ]
                  },
                   {
                        "title":"Practice Problem",  
                        "name" : "Compare Compounds",
                        "imagePath" : "slide63.PNG",
                        "question" : "Henry is 45-year old male who has recently been suffering from  what is believed to be absence seizures. Which compound should he be prescribed?",
                        "options" : [
                              "Compound 1", 
                              "Compound 2", 
                              "Compound 3"
                        ],
                        "answer" : "Compound 2",
                        "explanation" : "Ethosuximide (Compound 2); best used for absence seizures"
                  },
                   {
                        "title":"Practice Problem",  
                        "name" : "Compare Compounds",
                        "imagePath" : "slide64.PNG",
                        "question" : "Amir is 48-year old male who has recently been suffering from what is believed to be absence seizures. Unfortunately, ethosuximide was not effective, and it is decided that Amir needs a medication for partial seizures instead. Amir also is taking several other medications. Which compound should he take?",
                        "options" : [
                              "Compound 1", 
                              "Compound 2", 
                              "Compound 3"
                        ],
                        "answer" : "Compound 3",
                        "explanation" : ": Lamotrigine (Compound 3); not metabolized by CYP and does not induce CYP, which could interfere with other medications"
                  }
            ],
            "testItems":[
                  {
                        "title":"",  
                        "question" : "Antiepileptic drugs primarily reduce this activity",
                        "options" : [
                              "excitatory", 
                              "inhibitory "
                        ],
                        "answer" : "excitatory"
                  },
                  {
                        "title":"",  
                        "question" : "Consciousness is impaired for 30 seconds - 2 minutes by this seizure type: ",
                        "options" : [
                              "partial", 
                              "complex partial",
                              "absence "
                        ],
                        "answer" : "complex partial"
                  },
                  {
                        "title":"",  
                        "question" : "Antiepileptic drugs targeting sodium channels block",
                        "options" : [
                              "Sodium efflux",
                              "normal action potentials",
                              "epileptiform discharges"
                        ],
                        "answer" : "epileptiform discharges"
                  },
                  {
                        "title":"",  
                        "question" : "Antiepileptic drugs primarily enhance this activity",
                        "options" : [
                              "excitatory", 
                              "inhibitory "
                        ],
                        "answer" : "inhibitory"
                  },
                  {
                        "title":"",  
                        "question" : "Felbamate is an antiepileptic that blocks these receptors",
                        "options" : [
                              "AMPA", 
                              "dopamine",
                              "GABA",
                              "NMDA"
                        ],
                        "answer" : "GABA"
                  },
                  {
                        "title":"",  
                        "question" : "Reducing seizures and weight is possible with this anticonvulsant drug",
                        "options" : [
                              "topiramate", 
                              "valproic acid",
                              "gabapentin"
                        ],
                        "answer" : "topiramate"
                  },
                  {
                        "title":"",  
                        "question" : "Ethosuximide acts by inhibiting the activity of these channels",
                        "options" : [
                              "Calcium",
                              "Sodium",
                              "Chloride",
                              "Potassium"
                        ],
                        "answer" : "Calcium"
                  },
                  {
                        "title":"",  
                        "question" : "Ethosuximide is only used for this type of seizure",
                        "options" : [
                              "complex",
                              "partial",
                              "absence "
                        ],
                        "answer" : "absence"
                  },
                  {
                        "title":"",  
                        "question" : "This drug induces its own metabolism",
                        "options" : [
                              "Phenytoin", 
                              "Carbamazepine",
                              "Gabapentin"
                        ],
                        "answer" : "Carbamazepine"
                  },
                  {
                        "title":"",  
                        "question" : "Steven's Johnson syndrome is a rare but serious side effect of",
                        "options" : [
                              "Levetiracetam", 
                              "Lamotrigine",
                              "Carbamazepine"
                        ],
                        "answer" : "Lamotrigine"
                  },
                  {
                        "title":"",  
                        "question" : "Dizziness and somnolence is the most common side effect of",
                        "options" : [
                              "Phenytoin & Gabapentin", 
                              "Pregabalin & Phenobarbital",
                              "Pregabalin & Gabapentin",
                              "Phenobarbital & Gabapentin"
                        ],
                        "answer" : "Pregabalin & Gabapentin"
                  },
                  {
                        "title":"",  
                        "question" : "This binds to a synaptic vesicle protein and reduces presynaptic neurotransmitter release mediated by Ca2+",
                        "options" : [
                              "Levetiracetam", 
                              "Lamotrigine",
                              "topiramate"
                        ],
                        "answer" : "Levetiracetam"
                  },
                  {
                        "title":"",  
                        "question" : "Carbamazepine can be administered most safely without interaction with",
                        "options" : [
                              "lorazepam", 
                              "phenytoin",
                              "diazepam"
                        ],
                        "answer" : "diazepam"
                  },
                  {
                        "title":"",  
                        "question" : "This is an irreversible inhibitor of GABA transaminase",
                        "options" : [
                              "Gabapentin", 
                              "Pregabalin",
                              "Valproic acid",
                              "Vigabatrin "
                        ],
                        "answer" : "Vigabatrin"
                  }

            ], 
            "reviewItems":[
                  {
                        "title": "Epilepsy",  
                        "sections" : [
                              {"title": "Pathophysiology of a seizure", "content": "" },
                              {"title": "Common toxicities of many antiepileptic drugs", "content": "" }, 
                              {"title": "Notes", "content": "" }
                        ]
                  },
                  {
                        "title": "Molecular Targets for Epilepsy Treatment",  
                        "sections" : [
                              {"title": "Decrease Excitatory Activity", "content": "" },
                              {"title": "Increase Inhibitory Activity", "content": "" }
                        ]
                  },
                  {
                        "title": "(Target/MOA: Ca+ Channel) Treatment Drugs",  
                        "sections" : [
                              {"title": "Target/MOA", "content": "" },
                              {"title": "Neurotransmitter", "content": "" },
                              {"title": "Drugs", "content": "" }
                        ]
                  },
                  {
                        "title": "(Target/MOA: Na+ Channel) Treatment Drugs",  
                        "sections" : [
                              {"title": "Target/MOA", "content": "" },
                              {"title": "Neurotransmitter", "content": "" },
                              {"title": "Drugs", "content": "" }
                        ]
                  },
                  {
                        "title": "(Target/MOA: Synaptic Vesicle Protein) Treatment Drugs",  
                        "sections" : [
                              {"title": "Target/MOA", "content": "" },
                              {"title": "Neurotransmitter", "content": "" },
                              {"title": "Drugs", "content": "" }
                        ]
                  },
                  {
                        "title": "(Target/MOA: PAM @ GABA-A) Treatment Drugs",  
                        "sections" : [
                              {"title": "Target/MOA", "content": "" },
                              {"title": "Neurotransmitter", "content": "" },
                              {"title": "Drugs", "content": "" }
                        ]
                  },
                  {
                        "title": "(Target/MOA: GABA Metabolism) Treatment Drugs",  
                        "sections" : [
                              {"title": "Target/MOA", "content": "" },
                              {"title": "Neurotransmitter", "content": "" },
                              {"title": "Drugs", "content": "" }
                        ]
                  }
            ],
             "exampleReview":[
                  {
                        "title": "Epilepsy",  
                        "sections" : [
                              {"title": "Pathophysiology of a seizure", "content": "Finite episodes of brain dysfunction resulting from abnormal repetitive discharge of cerebral neurons." },
                              {"title": "Common toxicities of many antiepileptic drugs", "content": "Sedation, Rashes, Teratogenicity, Cerebellar: Ataxia & Nystagmus, CYP450 Interactions." }, 
                              {"title": "Notes", "content": "Anti-epileptics do not block ALL action potentials - blocking all would cause death." }
                        ]
                  },
                  {
                        "title": "Molecular Targets for Epilepsy Treatment",  
                        "sections" : [
                              {"title": "Decrease Excitatory Activity", "content": "*Works at Glutamatergic synapse. 1. Block NA+ Channels. 2. Block Ca+ Channels. 3. Activate K+ Channels. 4. Block NMDA-Receptor. 5. Block NMDA-Receptor. 6. Bind to Synaptic Vesicle Proteins." },
                              {"title": "Increase Inhibitory Activity", "content": "*Works at GABAergic synapse. 1. Block GABA Transporter (More GABA in synapse). 2. Block GABA Transaminase (Block metabolism of GABA). 3. Increase potency of GABA @ GABA-A Receptor." }
                        ]
                  },
                  {
                        "title": "(Ca+ Channel) Epilepsy Treatment",  
                        "sections" : [
                              {"title": "Target/MOA", "content": "Decrease Ca+ Channel Activity" },
                              {"title": "Neurotransmitter", "content": "Glutamate (Decrease excitatory activity)" },
                              {"title": "Drugs", "content": "Phenobarbital, Ethosuximide, Valproic Aid, Gabapentin, Pregabalin" }
                        ]
                  },
                  {
                        "title": "(Na+ Channel) Epilepsy Treatment",  
                        "sections" : [
                              {"title": "Target/MOA", "content": "Decrease Na+ Channel Activity" },
                              {"title": "Neurotransmitter", "content": "Glutamate (Decrease excitatory activity)" },
                              {"title": "Drugs", "content": "Phenytoin, Carbamazepine, Valproic Acid, Lamotrigine, Topiramate" }
                        ]
                  },
                  {
                        "title": "(Synaptic Vesicle Protein) Epilepsy Treatment",  
                        "sections" : [
                              {"title": "Target/MOA", "content": "Binds to synaptic vesicle protein to reduce presynaptic NT release" },
                              {"title": "Neurotransmitter", "content": "Glutamate (Decrease excitatory activity)" },
                              {"title": "Drugs", "content": "Levetiracetam" }
                        ]
                  },
                  {
                        "title": "(PAM @ GABA-A) Epilepsy Treatment",  
                        "sections" : [
                              {"title": "Target/MOA", "content": "PAM @ GABA-A" },
                              {"title": "Neurotransmitter", "content": "GABA (increase inhibitory activity)" },
                              {"title": "Drugs", "content": "Phenobarbital, Diazepam, Lorazepam" }
                        ]
                  },
                  {
                        "title": "(GABA Metabolism) Epilepsy Treatment",  
                        "sections" : [
                              {"title": "Target/MOA", "content": "Inhibition of GABA metabolism" },
                              {"title": "Neurotransmitter", "content": "GABA (increase inhibitory activity)" },
                              {"title": "Drugs", "content": "Valproic Acid" }
                        ]
                  }
            ]
      },
      {
            "id": 5,
            "name": "SRIs",
            "learnItems":[
                  {
                        "title":"SAR Requirements",  
                        "name" : "Phenoxyphenylalkyl Amines",
                        "imagePath" : "slide3.PNG",
                        "colorLocationAssociations" : [
                              {"color": "green", "location": "Basic Nitrogen", "description" : "Basic nitrogen: protonated at physiological pH; pKa 8.7−9.8" },
                              {"color": "deeppink", "location": "Electron-withdrawing group", "description" : "Electron-withdrawing group: para or meta substitution enhances binding affinity for SERT; while Ortho substitution (except CF3) enhances binding affinity for NET and results in NRI" },
                              {"color": "red", "location": "Phenoxy", "description" : "Phenoxy: distinguishes antidepressant and antihistamine activity (derived from diphenhydramine)." }
                        ]
                  },
                  {
                        "title":"Phenoxyphenylalkyl Amines Example",  
                        "name" : "Fluoxetine",
                        "imagePath" : "slide-5a.PNG",
                        "colorLocationAssociations" : [
                               {"color": "green", "location": "Basic Nitrogen", "description" : "Basic nitrogen: protonated at physiological pH; pKa 8.7−9.8" },
                              {"color": "deeppink", "location": "Electron-withdrawing group", "description" : "Electron-withdrawing group: para or meta substitution enhances binding affinity for SERT; while Ortho substitution (except CF3) enhances binding affinity for NET and results in NRI" },
                              {"color": "red", "location": "Phenoxy", "description" : "Phenoxy: distinguishes antidepressant and antihistamine activity (derived from diphenhydramine)." }
                        ]
                  },
                  {
                        "title":"SAR Requirements",  
                        "name" : "Phenylalkyl Amines",
                        "imagePath" : "slide4.PNG",
                        "colorLocationAssociations" : [
                              {"color": "green", "location": "Basic Nitrogen", "description" : "Basic nitrogen: protonated at physiological pH; pKa 9.5" },
                              {"color": "deeppink", "location": "Chlorine", "description" : "Chlorine: enhances SERT selectivity" }
                        ]
                  },
                  {
                        "title":"Phenylalkyl Amines Example",  
                        "name" : "Sertraline",
                        "imagePath" : "slide-5b.PNG",
                        "colorLocationAssociations" : [
                              {"color": "green", "location": "Basic Nitrogen", "description" : "Basic nitrogen: protonated at physiological pH; pKa 9.5" },
                              {"color": "deeppink", "location": "Chlorine", "description" : "Chlorine: enhances SERT selectivity" }
                        ]
                  },
                  {
                        "title":"SAR Practice Problem",  
                        "name" : "Activity Change",
                        "imagePath" : "slide7.PNG",
                        "question" : "Would the following change to the compound increase, decrease, or have no effect upon activity at SERT?",
                        "options" : [
                              "Increase", 
                              "Decrease", 
                              "No Effect"
                        ],
                        "answer" : "Decrease",
                        "explanation" : "The presence of an EWG (CF3) increases SERT activity of phenoxyphenylalkyl amines"
                  },
                  {
                        "title":"SAR Practice Problem",  
                        "name" : "Activity Change",
                        "imagePath" : "slide8.PNG",
                        "question" : "Would the following change to the compound increase, decrease, or have no effect upon activity at SERT?",
                        "options" : [
                              "Increase", 
                              "Decrease", 
                              "No Effect"
                        ],
                        "answer" : "Increase",
                        "explanation" : "The presence of the phenoxy (O directly attached to phenyl ring) distinguishes SRIs from diphenhydramine"
                  },
                  {
                        "title":"SAR Practice Problem",  
                        "name" : "Activity Change",
                        "imagePath" : "slide9.PNG",
                        "question" : "Would the following change to the compound increase, decrease, or have no effect upon activity at SERT?",
                        "options" : [
                              "Increase", 
                              "Decrease", 
                              "No Effect"
                        ],
                        "answer" : "Increase",
                        "explanation" : "The S isomer of fluoxetine is 100x more selective for SERT"
                  },
                  {
                        "title":"SAR Practice Problem",  
                        "name" : "Activity Change",
                        "imagePath" : "slide10.PNG",
                        "question" : "Would the following change to the compound increase, decrease, or have no effect upon activity at SERT?",
                        "options" : [
                              "Increase", 
                              "Decrease", 
                              "No Effect"
                        ],
                        "answer" : "Decrease",
                        "explanation" : "Ortho EWG substitution results in NRI and decreases SERT affinity"
                  },
                  {
                        "title":"SAR Practice Problem",  
                        "name" : "Compare Compounds",
                        "imagePath" : "slide12.PNG",
                        "question" : "Which of these 3 antidepressants has major side effects as GI upset and sexual dysfunction?",
                        "options" : [
                              "Compound 1", 
                              "Compound 2", 
                              "Compound 3"
                        ],
                        "answer" : "Compound 1",
                        "explanation" : "Paroxetine is an SRI, which commonly shows these adverse events"
                  },
                  {
                        "title":"SAR Practice Problem",  
                        "name" : "Compare Compounds",
                        "imagePath" : "slide13.PNG",
                        "question" : "Which of these 3 antidepressants is most selective for SERT?",
                        "options" : [
                              "Compound 1", 
                              "Compound 2", 
                              "Compound 3"
                        ],
                        "answer" : "Compound 3",
                        "explanation" : "Sertraline is an SRI, which is selective for SERT. Compound 1 is an NRI and compound 2 is a secondary amine TCA, which is more selective for NET."
                  },
                  {
                        "title":"SAR Practice Problem",  
                        "name" : "Predict Metabolite Activity",
                        "imagePath" : "slide15.PNG",
                        "question" : "Predict whether the metabolites will be active or inactive for the compounds (1, 3)",
                        "options" : [ 
                              "Active, Active",
                              "Active, Inactive",
                              "Inactive, Active",
                              "Inactive, Inactive"
                        ],
                        "answer" : "Inactive, Active",
                        "explanation" : ""
                  }
            ],
            "testItems":[
                  {
                        "title":"",  
                        "question" : "Escitalopram, fluoxetine, sertraline, and citalopram are examples of:",
                        "options" : [
                              "Tricyclic antidepressants",
                              "Atypical antidepressants",
                              "Norepinephrine Reuptake Inhibitors",
                              "Serotonin Reuptake Inhibitors"
                        ],
                        "answer" : "Serotonin Reuptake Inhibitors"
                  },
                  {
                        "title":"",  
                        "question" : "___________ are the most widely prescribed antidepressants",
                        "options" : [
                              "TCAs",
                              "SRIs",
                              "Lithium",
                              "SNRIs"
                        ],
                        "answer" : "SRIs"
                  },
                  {
                        "title":"",  
                        "question" : "__________ inhibits CYPs more significantly than other _______",
                        "options" : [
                              "(Escitalopram, TCAs)",
                              "(Sertraline, Atypical Antidepressants)",
                              "(Fluoxetine, SRIs)",
                              "(Citalopram, NRIs)"
                        ],
                        "answer" : "(Fluoxetine, SRIs)"
                  },
                  {
                        "title":"",  
                        "question" : "The most common adverse effects of SRIs GI and ________________",
                        "options" : [
                              "sexual side effects",
                              "orthostatic hypotension",
                              "constipation",
                              "drowsiness"
                        ],
                        "answer" : "sexual side effects"
                  },
                  {
                        "title":"",  
                        "question" : "SRIs have common drug interactions with _______ and can cause elevated levels of __________",
                        "options" : [
                              "(Acetylcholinesterase inhibitors, Acetylcholine)",
                              "(Anticonvulsants, Norepinephrine)",
                              "(Antibiotics, Dopamine)",
                              "(MAOIs, Serotonin)"
                        ],
                        "answer" : "(MAOIs, Serotonin)"
                  },
                  {
                        "title":"",  
                        "question" : "_________ can be recognized with side effects such as increased heart rate and diarrhea",
                        "options" : [
                              "Orthostatic Hypotension,",
                              "Antihistaminic Effects,",
                              "Serotonin Syndrome",
                              "Antimuscarinic Effects"
                        ],
                        "answer" : "Serotonin Syndrome"
                  },
                  {
                        "title":"",  
                        "question" : "SRIs are ________ tolerated than TCA",
                        "options" : [
                              "more",
                              "less",
                              "equally"
                        ],
                        "answer" : "more"
                  },
                  {
                        "title":"",  
                        "question" : "Abrupt withdrawal of SRIs can cause:",
                        "options" : [
                              "physical dependence",
                              "rebound effect",
                              "hangover",
                              "medullary depression"
                        ],
                        "answer" : "rebound effect"
                  }
            ], 
            "reviewItems":[
                  {
                        "title": "Drugs",  
                        "sections" : [
                              {"title": "Paroxetine (Pheno)", "imagePath": "paroxetine.PNG" },
                              {"title": "Escitalopram (Pheno)", "imagePath": "escitalopram.PNG" }, 
                              {"title": "Fluoxetine (Pheno)", "imagePath": "fluoxetine.PNG" },
                              {"title": "Sertraline (Pheny)", "imagePath": "sertraline.PNG" }
                        ]
                  },
                  {
                        "title": "SAR Characteristics - Phenoxyphenylalkyl Amines",  
                        "sections" : [
                              {"title": "Phenoxyphenylalkyl Amines", "imagePath": "sarCharacteristics-pheno.PNG" },
                              {"title": "", "content": "" },
                              {"title": "", "content": "" }, 
                              {"title": "", "content": "" }
                        ]
                  },
                  {
                        "title": "SAR Characteristics - Phenylalkyl Amine",  
                        "sections" : [
                              {"title": "Phenylalkyl Amine", "imagePath": "sarCharacteristics-pheny.PNG" },
                              {"title": "", "content": "" },
                              {"title": "", "content": "" }
                        ]
                  },
                  {
                        "title": "Action",  
                        "sections" : [
                              {"title": "Mechanism of Action", "imagePath": "mechanismAction.PNG" },
                              {"title": "Explanation", "content": "" },
                              {"title": "Acute SRI Use", "content": "" },
                              {"title": "Chronic SRI Use", "content": "" }
                        ]
                  },
                  {
                        "title": "Side-Effects",  
                        "sections" : [
                              {"title": "Side-Effects", "content": "" }
                        ]
                  },
                  {
                        "title": "Uses",  
                        "sections" : [
                              {"title": "Uses", "content": "" }
                        ]
                  },
                  {
                        "title": "Notes",  
                        "sections" : [
                              {"title": "Notes", "content": "" }
                        ]
                  }
            ],
             "exampleReview":[
                  {
                        "title": "Drugs",  
                        "sections" : [
                              {"title": "Paroxetine (Pheno)", "imagePath": "paroxetine.PNG" },
                              {"title": "Escitalopram (Pheno)", "imagePath": "escitalopram.PNG" }, 
                              {"title": "Fluoxetine (Pheno)", "imagePath": "fluoxetine.PNG" },
                              {"title": "Sertraline (Pheny)", "imagePath": "sertraline.PNG" }
                        ]
                  },
                  {
                        "title": "SAR Characteristics - Phenoxyphenylalkyl Amines",  
                        "sections" : [
                              {"title": "Phenoxyphenylalkyl Amines", "imagePath": "sarCharacteristics-pheno.PNG" },
                              {"title": "Basic nitrogen: ", "content": "protonated at physiological pH; pKa 8.7−9.8" },
                              {"title": "Electron-withdrawing group: ", "content": "para or meta substitution enhances binding affinity for SERT. -Ortho substitution (except CF3) enhances binding affinity for NET and results in NRI" }, 
                              {"title": "Phenoxy:", "content": "distinguishes antidepressant and antihistamine activity (derived from diphenhydramine)" }
                        ]
                  },
                  {
                        "title": "SAR Characteristics - Phenylalkyl Amine",  
                        "sections" : [
                              {"title": "Phenylalkyl Amine", "imagePath": "sarCharacteristics-pheny.PNG" },
                              {"title": "Basic Nitrogen", "content": "Protonated at physiological pH; pKa 9.5" },
                              {"title": "Chlorine", "content": "enhances SERT selectivity" }
                        ]
                  },
                  {
                        "title": "Action",  
                        "sections" : [
                              {"title": "Mechanism of Action", "imagePath": "mechanismAction.PNG" },
                              {"title": "Explanation", "content": "Blocks Serotonin Transporter (SERT) on pre-synaptic neuron resulting in increased serotonin in the synapse which is available to bind to post synaptic serotonin receptors." },
                              {"title": "Acute SRI Use", "content": "1. Drug blocks 5-HT re-update (SERT) 2. Auto receptor (5-HT1A) activity decreases 3. 5-HT release decreases" },
                              {"title": "Chronic SRI Use", "content": "1. Auto receptor (5-HT1A) function is lost 2. 5-HT release returns to normal 3. Now serotonin in synapse is greatly increased" }
                        ]
                  },
                  {
                        "title": "Side-Effects",  
                        "sections" : [
                              {"title": "Side-Effects", "content": "Nausea & GI symptoms, Sexual effects (decreased libido & sexual dysfunction), Mild restlessness, Mild headaches, Mild Insomnia" }
                        ]
                  },
                  {
                        "title": "Uses",  
                        "sections" : [
                              {"title": "Uses", "content": "Depression, OCD, panic disorder, anxiety" }
                        ]
                  },
                  {
                        "title": "Notes",  
                        "sections" : [
                              {"title": "Notes", "content": "SRIs compete with metabolism of other drugs, Never use in combo with MAOIs (MAOIs inhibit breakdown of SRIs and could lead to overdose of serotonin in the brain)" }
                        ]
                  }
            ]
      },
      {
            "id": 6,
            "name": "SNRIs",
            "learnItems":[
                  {
                        "title":"Helpful Strucures to Know",  
                        "name" : "Duloxetine",
                        "imagePath" : "slide-23a.PNG",
                        "colorLocationAssociations" : [
                              {"color": "black", "location": "None", "description" : "Serotonin and Norepinephrine Reuptake Inhibitors do not have any Structure Activity Requirements but these are some helpful structures to be familiar with." }
                        ]
                  },
                  {
                        "title":"Helpful Strucures to Know",  
                        "name" : "Venlafaxine",
                        "imagePath" : "slide-23b.PNG",
                        "colorLocationAssociations" : [
                              {"color": "black", "location": "None", "description" : "Serotonin and Norepinephrine Reuptake Inhibitors do not have any Structure Activity Requirements but these are some helpful structures to be familiar with." }
                        ]
                  },
                  {
                        "title":"SAR Practice Problem",  
                        "name" : "Compare Compounds",
                        "imagePath" : "slide25.PNG",
                        "question" : "Which of these 3 antidepressants is active at both SERT and NET?",
                        "options" : [
                              "Compound 1", 
                              "Compound 2", 
                              "Compound 3"
                        ],
                        "answer" : "Compound 2",
                        "explanation" : "Duloxetine is an SNRI, which is active at SERT and NET. Compound 1 is SRI and Compound 3 is bupropion, which weakly blocks DAT and NET"
                  },
                  {
                        "title":"SAR Practice Problem",  
                        "name" : "Compare Compounds",
                        "imagePath" : "slide26.PNG",
                        "question" : "Which of these 3 antidepressants is considered activating and may raise blood pressure?",
                        "options" : [
                              "Compound 1", 
                              "Compound 2", 
                              "Compound 3"
                        ],
                        "answer" : "Compound 3",
                        "explanation" : " Venlafaxine is an SNRI, which is known to be activating"
                  },
                  {
                        "title":"SAR Practice Problem",  
                        "name" : "Clinical Case Study ",
                        "imagePath" : "slide28.PNG",
                        "question" : "Alfred Smith is 80-year old male suffering from depression. He is currently taking paroxetine, but it is not helping. What one compound would you recommend he try next?",
                        "options" : [
                              "Compound 1", 
                              "Compound 2", 
                              "Compound 3"
                        ],
                        "answer" : "Compound 3",
                        "explanation" : "Compound 1 is an SRI, which he was currently taking and not helping. Compound 2 is a tertiary amine TCA, which acts as a SNRI and would be helpful, but leads to adverse effects such as sedation and hypotension so not recommended in elderly. Compound 3 (venlafaxine) is best choice as it is SNRI, with few adverse effects."
                  }
            ],
            "testItems":[
                  {
                        "title":"",  
                        "question" : "Venlafaxine and duloxetine are examples of: ",
                        "options" : [
                              "Tricyclic Antidepressants",
                              "Atypical Antidepressants",
                              "Serotonin-Norepinephrine Reuptake Inhibitors",
                              "Selective Serotonin Reuptake Inhibitors"
                        ],
                        "answer" : "Serotonin-Norepinephrine Reuptake Inhibitors"
                  },
                  {
                        "title":"",  
                        "question" : "SNRI’s have _________ effects such as agitation",
                        "options" : [
                              "seratonergic",
                              "noradrenergic",
                              "histaminergic",
                              "cholinergic"
                        ],
                        "answer" : "noradrenergic"
                  },
                  {
                        "title":"",  
                        "question" : "(venlafaxine/duloxetine) is more potent than (venlafaxine/duloxetine)",
                        "options" : [
                              "(venlafaxine, duloxetine)",
                              "(duloxetine, venlafaxine)"
                        ],
                        "answer" : "(venlafaxine, duloxetine)"
                  },
                  {
                        "title":"",  
                        "question" : "SNRI’s are similar to TCA potency, have (less/more) side effects, and (faster/slower) than SRI alone",
                        "options" : [
                              "(less, faster)",
                              "(more, slower)",
                              "(more, faster)",
                              "(less, slower)"
                        ],
                        "answer" : "(less, faster)"
                  },
                  {
                        "title":"",  
                        "question" : "_________ has an active metabolite",
                        "options" : [
                              "Duloxetine",
                              "Sibutramine",
                              "Venlafaxine",
                              "Milnacipran"
                        ],
                        "answer" : "Venlafaxine"
                  },
                  {
                        "title":"",  
                        "question" : "BONUS: Venlafaxine's active metabolite's name is:",
                        "options" : [
                              "Ansofaxine",
                              "Duloxetine",
                              "Atomoxetine",
                              "Desvenlafaxine"
                        ],
                        "answer" : "Desvenlafaxine"
                  }
            ], 
            "reviewItems":[]
      },
      {
            "id": 7,
            "name": "Tricyclic-Antidepressants",
            "learnItems":[
                  {
                        "title":"SAR Requirements",  
                        "name" : "Tertiary Amines",
                        "imagePath" : "slide34.PNG",
                        "colorLocationAssociations" : [
                              {"color": "red", "location": "Linker of 3 carbons", "description" : "Linker of 3 carbons between tricyclic ring system and basic nitrogen. Branching from linker decreases binding affinity for SERT and NET. Unsaturation of linker is tolerated." },
                              {"color": "deeppink", "location": "R→ CH3", "description" : "R→ CH3, tertiary amine imparts selectivity for SERT" },
                              {"color": "blue", "location": "R’→ Cl or CN (EWG)", "description" : "R’→ Cl or CN (EWG) enhances binding affinity for SERT" },
                              {"color": "green", "location": "Y→ can be C or N", "description" : "Y→ can be C or N" },
                              {"color": "purple", "location": "Conformationally rigid [6.7.6]-fused ring system", "description" : "Conformationally rigid [6.7.6]-fused ring system - 7 membered ring in the middle is not coplanar; results in twisted shape" }
                        ]
                  },
                  {
                        "title":"Tertiary Amines Example Compound",  
                        "name" : "Clomipramine",
                        "imagePath" : "slide-36a.PNG",
                        "colorLocationAssociations" : []
                  },
                  {
                        "title":"SAR Requirements",  
                        "name" : "Secondary Amines",
                        "imagePath" : "slide35.PNG",
                        "colorLocationAssociations" : [
                              {"color": "red", "location": "Linker of 3 carbons", "description" : "Linker of 3 carbons between tricyclic ring system and basic nitrogen. Branching from linker decreases binding affinity for SERT and NET. Unsaturation of linker is tolerated." },
                              {"color": "deeppink", "location": "R→ CH3", "description" : "R→ H, secondary amine imparts selectivity for NET" },
                              {"color": "blue", "location": "R’→ Cl or CN (EWG)", "description" : "R’→ no substitution decreases SERT preference" },
                              {"color": "green", "location": "Y→ can be C or N", "description" : "Y→ can be C or N" },
                              {"color": "purple", "location": "Conformationally rigid [6.7.6]-fused ring system", "description" : "Conformationally rigid [6.7.6]-fused ring system - 7 membered ring in the middle is not coplanar; results in twisted shape" }
                        ]
                  },
                  {
                        "title":"Secondary Amines Example Compound",  
                        "name" : "Nortriptyline",
                        "imagePath" : "slide-36b.PNG",
                        "colorLocationAssociations" : []
                  },
                  {
                        "title":"SAR Practice Problem",  
                        "name" : "Activity Change",
                        "imagePath" : "slide38.PNG",
                        "question" : "Would the following change to the compound increase, decrease, or have no effect upon activity at SERT?",
                        "options" : [
                              "Increase", 
                              "Decrease", 
                              "No Effect"
                        ],
                        "answer" : "Decrease",
                        "explanation" : "Tertiary→ Secondary amine decreases binding affinity for SERT"
                  },
                  {
                        "title":"SAR Practice Problem",  
                        "name" : "Activity Change",
                        "imagePath" : "slide39.PNG",
                        "question" : "Would the following change to the compound increase, decrease, or have no effect upon activity at SERT?",
                        "options" : [
                              "Increase", 
                              "Decrease", 
                              "No Effect"
                        ],
                        "answer" : "Increase",
                        "explanation" : "Presence of EWG (Cl) enhances binding affinity for SERT"
                  },
                  {
                        "title":"SAR Practice Problem",  
                        "name" : "Compare Compounds",
                        "imagePath" : "slide41.PNG",
                        "question" : "Which of these 3 antidepressants is active at both SERT and NET?",
                        "options" : [
                              "Compound 1", 
                              "Compound 2", 
                              "Compound 3"
                        ],
                        "answer" : "Compound 2",
                        "explanation" : "Compound 2, amitriptyline is a tertiary TCA, which is active at SERT and NET. Compound 1 is SRI and Compound 3 is a secondary TCA, only active at NET"
                  },
                  {
                        "title":"SAR Practice Problem",  
                        "name" : "Compare Compounds",
                        "imagePath" : "slide42.PNG",
                        "question" : "Which of these 3 antidepressants causes significant dry mouth, constipation, and sedation?",
                        "options" : [
                              "Compound 1", 
                              "Compound 2", 
                              "Compound 3"
                        ],
                        "answer" : "Compound 1",
                        "explanation" : "Compound 1, clomipramine is a tertiary TCA, which is can bind to muscarinic and histamine receptors resulting in off target adverse effects. Compound 2 is a SRI and does not cause these adverse effects. Compound 3 is a mirtazepine and while it can cause sedation, it does not display anticholinergic effects such as dry mouth and constipation."
                  },
                  {
                        "title":"SAR Practice Problem",  
                        "name" : "Predict Metabolite Activity",
                        "imagePath" : "slide44.PNG",
                        "question" : "Predict whether the metabolites will be active or inactive for the compound products. Would amitriptyline be an ideal antidepressant for the elderly?",
                        "options" : [ 
                              "Active, Active, Yes",
                              "Active, Inactive, No", 
                              "Inactive, Inactive, No",
                              "Inactive, Active, Yes"
                        ],
                        "answer" : "Active, Inactive, No",
                        "explanation" : "Aamitriptyline causes anticholinergic effects, therefore it is not an ideal antidepressant for the elderly."
                  },
                  {
                        "title":"SAR Practice Problem",  
                        "name" : "Predict Metabolite Activity",
                        "imagePath" : "slide45.PNG",
                        "question" : "Predict whether the metabolites will be active or inactive for the compound products",
                        "options" : [ 
                              "Active, Active",
                              "Active, Inactive", 
                              "Inactive, Inactive",
                              "Inactive, Active"
                        ],
                        "answer" : "Active, Inactive",
                        "explanation" : "No explanation for this item."
                  },
                  {
                        "title":"SAR Practice Problem",  
                        "name" : "Predict Metabolite Activity",
                        "imagePath" : "slide46.PNG",
                        "question" : "Predict whether the metabolites will be active or inactive for the compound product. Is nortriptyline considered an SNRI or NRI?",
                        "options" : [ 
                              "Active, NRI",
                              "Active, SNRI", 
                              "Inactive, NRI",
                              "Inactive, SNRI"
                        ],
                        "answer" : "Inactive, NRI",
                        "explanation" : "Nortriptyline is a secondary TCA so it is more selective for NET."
                  }
            ],
            "testItems":[
                  {
                        "title":"",  
                        "question" : "Tertiary TCAs have slightly greater selectivity for blockade of (Norepinephrine/Serotonin) reuptake over (Norepinephrine/Serotonin) reuptake",
                        "options" : [
                              "(Norepinephrine, Serotonin)",
                              "(Serotonin, Norepinephrine)"
                        ],
                        "answer" : "(Serotonin, Norepinephrine)"
                  },
                  {
                        "title":"",  
                        "question" : "Secondary TCA’s, such as (Nortriptyline/Amitriptyline) have greater selectivity for blockade of (Norepinephrine/Serotonin)",
                        "options" : [
                              "(Nortriptyline, Norepinephrine)",
                              "(Nortriptyline, Serotonin)",
                              "(Amitriptyline, Norepinephrine)",
                              "(Amitriptyline, Serotonin)"
                        ],
                        "answer" : "(Nortriptyline, Norepinephrine)"
                  },
                  {
                        "title":"",  
                        "question" : "TCA adverse effects include _____________ effects such as dry eyes and mouth",
                        "options" : [
                              "adrenergic",
                              "antihistaminic",
                              "anticholinergic",
                              "antimuscarinic"
                        ],
                        "answer" : "antimuscarinic"
                  },
                  {
                        "title":"",  
                        "question" : "Onset of action for TCA’s takes 2-3:",
                        "options" : [
                              "months",
                              "weeks",
                              "days",
                              "minutes"
                        ],
                        "answer" : "weeks"
                  },
                  {
                        "title":"",  
                        "question" : "Side effects include sexual dysfunction, constipation, and: ",
                        "options" : [
                              "prominent GI effects",
                              "sedation",
                              "migraines",
                              "blood disorders"
                        ],
                        "answer" : "sedation"
                  }
            ], 
            "reviewItems":[
                  {
                        "title": "Drugs",  
                        "sections" : [
                              {"title": "Amitriptyline (Tertiary)", "imagePath": "review-Amitriptyline.PNG" },
                              {"title": "Nortriptyline (Secondary)", "imagePath": "review-Nortriptyline.PNG" }
                        ]
                  },
                  {
                        "title": "SAR Characteristics",  
                        "sections" : [
                              {"title": "Example Compound", "imagePath": "review-sar.PNG" },
                              {"title": "", "content": "" },
                              {"title": "", "content": "" },
                              {"title": "", "content": "" }, 
                              {"title": "", "content": "" }, 
                              {"title": "", "content": "" }, 
                              {"title": "", "content": "" },  
                              {"title": "", "content": "" }
                        ]
                  },
                  {
                        "title": "Mechanism of Action",  
                        "sections" : [
                              {"title": "MOA", "imagePath": "moa-TCAs.PNG" },
                              {"title": "Explanation", "content": "" }
                        ]
                  },
                  {
                        "title": "Side-Effects",  
                        "sections" : [
                              {"title": "Side-Effects", "content": "" }
                        ]
                  },
                  {
                        "title": "Uses",  
                        "sections" : [
                              {"title": "Uses", "content": "" }
                        ]
                  },
                  {
                        "title": "Notes",  
                        "sections" : [
                              {"title": "Notes", "content": "" }
                        ]
                  }
            ],
            "exampleReview":[
                  {
                        "title": "Drugs",  
                        "sections" : [
                              {"title": "Amitriptyline (Tertiary)", "imagePath": "review-Amitriptyline.PNG" },
                              {"title": "Nortriptyline (Secondary)", "imagePath": "review-Nortriptyline.PNG" }
                        ]
                  },
                  {
                        "title": "SAR Characteristics",  
                        "sections" : [
                              {"title": "Example Compound", "imagePath": "review-sar.PNG" },
                              {"title": "Linker of 3 carbons", "content": "Linker of 3 carbons between tricyclic ring system and basic nitrogen. Branching from linker decreases binding affinity for SERT and NET. Unsaturation of linker is tolerated." },
                              {"title": "R→ CH3, tertiary amine", "content": "R→ CH3, tertiary amine imparts selectivity for SERT" },
                              {"title": "R→ H, secondary amine", "content": "R→ H, secondary amine imparts selectivity for NET" }, 
                              {"title": "R’→ Cl or CN (EWG)", "content": "R’→ Cl or CN (EWG) enhances binding affinity for SERT" }, 
                              {"title": "R’→ no substitution", "content": "R’→ no substitution decreases SERT preference" }, 
                              {"title": "Y→ can be C or N", "content": "Y→ can be C or N" },  
                              {"title": "Conformationally rigid [6.7.6]-fused ring system", "content": "Conformationally rigid [6.7.6]-fused ring system - 7 membered ring in the middle is not coplanar; results in twisted shape" }
                        ]
                  },
                  {
                        "title": "Mechanism of Action",  
                        "sections" : [
                              {"title": "MOA", "imagePath": "moa-TCAs.PNG" },
                              {"title": "Explanation", "content": "Block SERT & NET to inhibit seratonin and norepinephrine reuptake. Block muscarinic, Histamine H1, and Alpha adrenergic receptors" }
                        ]
                  },
                  {
                        "title": "Side-Effects",
                        "sections" : [
                              {"title": "Side-Effects", "content": "[Amitriptyline]: Sedation, Hypotension, Anti-Muscarinic, Weight Gain. [Nortiptyline]: No major side effects." }
                        ]
                  },
                  {
                        "title": "Notes",  
                        "sections" : [
                              {"title": "Notes", "content": "[Amitriptyline]: Can cause extreme CNS depression leading to death if OD. [Nortiptyline]: Selectively blocks NET with much more affinity than SERT." }
                        ]
                  }
            ]
      },
      {
            "id": 8,
            "name": "Atypical-Antidepressants",
            "learnItems":[
                  {
                        "title":"Useful Structures",  
                        "name" : "Trazodone",
                        "imagePath" : "slide-53a.PNG",
                        "colorLocationAssociations" : [
                              {"color": "black", "location": "none", "description" : "Circled parts of each structure are helpful to associate with the compounds. There are no SAR Requirements for Atypical Antidepressants" }
                        ]
                  },
                  {
                        "title":"Useful Structures",  
                        "name" : "Mirtazepine",
                        "imagePath" : "slide-53b.PNG",
                        "colorLocationAssociations" : [
                              {"color": "black", "location": "none", "description" : "Circled parts of each structure are helpful to associate with the compounds. There are no SAR Requirements for Atypical Antidepressants" }
                        ]
                  },
                  {
                        "title":"Useful Structures",  
                        "name" : "Bupropion",
                        "imagePath" : "slide-53c.PNG",
                        "colorLocationAssociations" : [
                              {"color": "black", "location": "none", "description" : "Circled parts of each structure are helpful to associate with the compounds. There are no SAR Requirements for Atypical Antidepressants" }
                        ]
                  },
                  {
                        "title":"Practice Problem",  
                        "name" : "Compare Compounds",
                        "imagePath" : "slide55.PNG",
                        "question" : "Which of these 3 antidepressants can also be used for smoking cessation?",
                        "options" : [
                              "Compound 1", 
                              "Compound 2", 
                              "Compound 3"
                        ],
                        "answer" : "Compound 2",
                        "explanation" : "Bupropion"
                  },
                  {
                        "title":"Practice Problem",  
                        "name" : "Compare Compounds",
                        "imagePath" : "slide56.PNG",
                        "question" : "Which of these 3 antidepressants causes sedation by blocking histamine receptors?",
                        "options" : [
                              "Compound 1", 
                              "Compound 2", 
                              "Compound 3"
                        ],
                        "answer" : "Compound 3",
                        "explanation" : "Mirtazepine"
                  },
                  {
                        "title":"Practice Problem",  
                        "name" : "Compare Compounds",
                        "imagePath" : "slide57.PNG",
                        "question" : "Which of these 3 antidepressants can result in a hepatotoxic metabolite?",
                        "options" : [
                              "Compound 1", 
                              "Compound 2", 
                              "Compound 3"
                        ],
                        "answer" : "Compound 2",
                        "explanation" : "Metabolism of Trazodone"
                  },
                  {
                        "title":"SAR Practice Problem",  
                        "name" : "Clinical Case Study ",
                        "imagePath" : "slide59.PNG",
                        "question" : "Mary Sue is 25-year old male suffering from depression. She complains of feeling tired and gaining weight with her last course of antidepressants. Which compound would you recommend her to try?",
                        "options" : [
                              "Compound 1", 
                              "Compound 2", 
                              "Compound 3"
                        ],
                        "answer" : "Compound 3",
                        "explanation" : "Compound 1 (trazodone) can cause sedation. Compound 2 (amitriptyline) can cause weight gain. Compound 3 (bupropion) would be a good alternative for this patient to prevent unwanted adverse effects."
                  }
            ],
            "testItems":[
                  {
                        "title":"",  
                        "question" : "Significant side effect of both trazodone and mirtazepine is: ",
                        "options" : [
                              "orthostatic hypotension",
                              "sedation",
                              "constipation",
                              "sexual effects"
                        ],
                        "answer" : "sedation"
                  },
                  {
                        "title":"",  
                        "question" : "Trazodone works by blocking the ______ serotonin receptor and being an agonist at the _______ serotonin receptor",
                        "options" : [
                              "(5HT_1A, 5HT_2A)",
                              "(5HT_1D, 5HT_2B)",
                              "(5HT_2A, 5HT_1A)",
                              "(5HT_2B, 5HT_1D)"
                        ],
                        "answer" : "(5HT_2A, 5HT_1A)"
                  },
                  {
                        "title":"",  
                        "question" : "Mirtazapine blocks a serotonin receptor and a ________ receptor",
                        "options" : [
                              "adrenergic",
                              "dopamine",
                              "histamine",
                              "muscarinic"
                        ],
                        "answer" : "histamine"
                  },
                  {
                        "title":"",  
                        "question" : "Buproprion has a potential for ___________ at high doses",
                        "options" : [
                              "seizures",
                              "dyskinesia",
                              "memory loss",
                              "respiratory depression"
                        ],
                        "answer" : "seizures"
                  },
                  {
                        "title":"",  
                        "question" : "__________ can cause increase appetite and weight gain while ___________ can have the opposite effect",
                        "options" : [
                              "(Mirtazapine, Buproprion)",
                              "(Buproprion, Mirtazapine)",
                              "(Trazodone, Buproprion)",
                              "(Buproprion, Trazodone)"
                              
                        ],
                        "answer" : "(Trazodone, Buproprion)"
                  },
                  {
                        "title":"",  
                        "question" : "______________ can be used a sleep aid independent of its antidepressant activity",
                        "options" : [
                              "Fluoxetine",
                              "Mirtazapine",
                              "Buproprion",
                              "Trazadone"
                        ],
                        "answer" : "Trazadone"
                  }
            ],
             "reviewItems":[
                  {
                        "title": "Atypical Antidepressants (Trazodone)",  
                        "sections" : [
                              {"title": "MOA", "content": "" },
                              {"title": "SAR", "imagePath": "trazodone.PNG", "content": "None"},
                              {"title": "Side Effects", "content": ""}
                        ]
                  },
                  {
                        "title": "Atypical Antidepressants (Mirtazapine)",  
                        "sections" : [
                              {"title": "MOA", "content": "" },
                              {"title": "SAR", "imagePath": "mirtazapine.PNG", "content": "None"},
                              {"title": "Side Effects", "content": ""}
                        ]
                  },
                  {
                        "title": "Atypical Antidepressants (Bupropion)",  
                        "sections" : [
                              {"title": "MOA", "content": "" },
                              {"title": "SAR", "imagePath": "bupropion.PNG", "content": "None"},
                              {"title": "Side Effects", "content": ""}
                        ]
                  },
                  {
                        "title": "SNRIs & SRIs (Venlafaxine)",  
                        "sections" : [
                              {"title": "MOA", "content": "" },
                              {"title": "SAR", "imagePath": "venlafaxine.PNG", "content": ""},
                              {"title": "Side Effects", "content": ""}
                        ]
                  },
                  {
                        "title": "SRIs (Escitalopram, Fluoxetine, Sertraline)",  
                        "sections" : [
                              {"title": "MOA", "content": "" },
                              {"title": "SAR", "imagePath": "sri-sar.PNG", "content": ""},
                              {"title": "Phenoxyphenylalkyl SAR", "content": ""},
                              {"title": "Phenylalkyl SAR", "content": ""},
                              {"title": "Side Effects", "content": ""}
                        ]
                  },
                  {
                        "title": "Tricyclic Antidepressants (Amitriptyline & Nortriptyline)",  
                        "sections" : [
                              {"title": "MOA", "content": "" },
                              {"title": "SAR", "imagePath": "triptyline.PNG", "content": ""},
                              {"title": "SAR Explained", "content": ""},
                              {"title": "Side Effects", "content": ""}
                        ]
                  },
                  {
                        "title": "THEORIES OF DEPRESSION",  
                        "sections" : [
                              {"title": "Monoamine Theory", "content": ""},
                              {"title": "Neurotrophic Theory", "content": ""}
                        ]
                  },
                  {
                        "title": "LOW NERUOTRANSMITTER LEVELS",  
                        "sections" : [
                              {"title": "Low serotonin", "content": ""},
                              {"title": "Low norepinephrine", "content": ""},
                              {"title": "Low dopamine", "content": ""}
                        ]
                  },
                  {
                        "title": "ACTIVATION OF RECEPTORS",  
                        "sections" : [
                              {"title": "5-HT", "content": ""},
                              {"title": "Adrenergic", "content": ""},
                              {"title": "Antihistamine H1", "content": ""},
                              {"title": "Alpha1-Adrenergic", "content": ""}
                        ]
                  }

            ],                     
            "exampleReview":[
                  {
                        "title": "Atypical Antidepressants (Trazodone)",  
                        "sections" : [
                              {"title": "MOA", "content": "Blocks SERT and alpha1-adrenergic receptor. Agonist at 5-HT1A on post-synaptic neuron." },
                              {"title": "SAR", "imagePath": "trazodone.PNG", "content": "None"},
                              {"title": "Side Effects", "content": "[Major]: Sedation. [Minor]: GI, Weight Gain."}
                        ]
                  },
                  {
                        "title": "Atypical Antidepressants (Mirtazapine)",  
                        "sections" : [
                              {"title": "MOA", "content": "Blocks H1 histamine receptor, 5HT2 receptor and alpha2-adrendergic receptor. Agonist at 5HT1A on post synaptic neuron." },
                              {"title": "SAR", "imagePath": "mirtazapine.PNG", "content": "None"},
                              {"title": "Side Effects", "content": "[Major]: Sedation. [Minor]: Weight Gain"}
                        ]
                  },
                  {
                        "title": "Atypical Antidepressants (Bupropion)",  
                        "sections" : [
                              {"title": "MOA", "content": "Blocks DAT and NET resulting in increased dopamine and NE in extracellular space - dopamine acts on reward pathway to improve mood." },
                              {"title": "SAR", "imagePath": "bupropion.PNG", "content": "None"},
                              {"title": "Side Effects", "content": "[Major]: Insomnia, Agitation. [Minor]: Nausea, Dry Mouth"}
                        ]
                  },
                  {
                        "title": "SNRIs & SRIs (Venlafaxine)",  
                        "sections" : [
                              {"title": "MOA", "content": "Blocks SERT and NET resulting in increased levels of serotinin and norepinephrine in the synapse." },
                              {"title": "SAR", "imagePath": "venlafaxine.PNG", "content": "None"},
                              {"title": "Side Effects", "content": "[Major]: GI, Sexual Effect."}
                        ]
                  },
                  {
                        "title": "SRIs (Escitalopram, Fluoxetine, Sertraline)",  
                        "sections" : [
                              {"title": "MOA", "content": "Selectively blocks SERT on the pre-synaptic neuron resulting in increased levels of serotonin in the synapse and increased activation of 5-HT1A receptors on post-synaptic neuron." },
                              {"title": "SAR", "imagePath": "sri-sar.PNG", "content": ""},
                              {"title": "Phenoxyphenylalkyl SAR", "content": "[Basic nitrogen]: protonated at physiological pH; pKa 8.7−9.8. [Electron-withdrawing group]: para or meta substitution enhances binding affinity for SERT. [Phenoxy]: distinguishes antidepressant and antihistamine activity derived from diphenhydramine)"},
                              {"title": "Phenylalkyl SAR", "content": "[Basic nitrogen]: protonated at physiological pH; pKa 9.5. [Chlorine]: enhances SERT selectivity."},
                              {"title": "Side Effects", "content": "[Major]: GI, Sexual Effect."}
                        ]
                  },
                  {
                        "title": "Tricyclic Antidepressants (Amitriptyline & Nortriptyline)",  
                        "sections" : [
                              {"title": "MOA", "content": "Blocks SET and NET on pre-synaptic neuron resulting in increased levels of serotonin and norepinephrine in the synapse. Some also acts as antagonists at 5HT2, Alpha1-adrenergic, histamine and muscarinic receptors." },
                              {"title": "SAR", "imagePath": "triptyline.PNG", "content": ""},
                              {"title": "SAR Explained", "content": "[Linker of 3 carbons]: between tricyclic ring system and basic nitrogen. Branching from linker decreases binding affinity for SERT and NET. Unsaturation of linker is tolerated. [R→ CH3]: tertiary amine imparts selectivity for SERT. [R’→ Cl or CN (EWG)]: enhances binding affinity for SERT. [Y→ can be C or N]. [Conformationally rigid [6.7.6]-fused ring system]: 7 membered ring in the middle is not coplanar; results in twisted shape"},
                              {"title": "Side Effects", "content": "[Major]: Weight gain, GI, Sexual Effect."}
                        ]
                  },
                  {
                        "title": "THEORIES OF DEPRESSION",  
                        "sections" : [
                              {"title": "Monoamine Theory", "content": "Deficiency of 5-HT and NE transmission in the CNS"},
                              {"title": "Neurotrophic Theory", "content": "Decrease of Brain Derived Neurotophic Factor (BDNF) resulting in reduced neuroplasticity, decreased number of spines and thus, decreased neurotransmission."}
                        ]
                  },
                  {
                        "title": "LOW NERUOTRANSMITTER LEVELS",  
                        "sections" : [
                              {"title": "Low serotonin", "content": "Anxiety, panic, phobia"},
                              {"title": "Low norepinephrine", "content": "Decreased concentration, decreased working memory, decreased information processing, fatigue."},
                              {"title": "Low dopamine", "content": "Cognitive slowing, hypersomnia, anhedonia"}
                        ]
                  },
                  {
                        "title": "ACTIVATION OF RECEPTORS",  
                        "sections" : [
                              {"title": "5-HT", "content": "GI and Nausea, Sexual Effects (decreased libido, sexual dysfunction), Mild Restlessness, Headaches and Insomnia"},
                              {"title": "Adrenergic", "content": "Agitation (awakening), small increases in blood pressure and heart rate"},
                              {"title": "Antihistamine H1", "content": "Sedation"},
                              {"title": "Alpha1-Adrenergic", "content": "Hypotension"}
                        ]
                  }

            ]            
      },
      {
            "id": 9,
            "name": "CWB-Inhibitors",
            "learnItems":[
                  {
                        "title":"SAR Requirements",  
                        "name" : "Fosfomycin: Hover over compound to view areas.",
                        "imagePath" : "slide2-fosfomycin.PNG",
                        "imgWidth" : 300,
                        "imgPadding" : 100,
                        "compoundHotspots" : [
                              {
                                    "name": "Reactive Epoxide Group",
                                    "y": 210,
                                    "x": 262,
                                    "size": 55,
                                    "color": "blue",
                                    "text": "Reactive Epoxide Group"
                              },
                              {
                                    "name": "PEP Mimic",
                                    "y": 270,
                                    "x": 142,
                                    "size": 75,
                                    "color": "red",
                                    "text": "PEP Mimic"
                              }
                        ]
                  },
                  {
                        "title":"SAR Requirements",  
                        "name" : "Cycloserine: Hover over compound to view areas.",
                        "imagePath" : "slide2-cycloserine.PNG",
                        "compoundHotspots" : [
                              {
                                    "name": "D-Ala analogue",
                                    "y": 260,
                                    "x": 154,
                                    "size": 120,
                                    "color": "red",
                                    "text": "D-Ala analogue"
                              },
                              {
                                    "name": "5-membered ring",
                                    "y": 254,
                                    "x": 264,
                                    "size": 50,
                                    "color": "blue",
                                    "text": "5-membered ring"
                              }
                        ]
                        
                  },
                  {
                        "title":"SAR Requirements",  
                        "name" : "Bacitracin: Hover over compound to view areas.",
                        "imagePath" : "slide3-bacitracin.PNG",
                        "imgWidth" : 500,
                        "imgPadding" : 75,
                        "compoundHotspots" : [
                              {
                                    "name": "Peptide Bond",
                                    "y": 310,
                                    "x": 207,
                                    "size": 40,
                                    "color": "red",
                                    "text": "Bacitracin contains many peptide bonds"
                              },
                              {
                                    "name": "Peptide Bond",
                                    "y": 310,
                                    "x": 323,
                                    "size": 40,
                                    "color": "red",
                                    "text": "Bacitracin contains many peptide bonds"
                              }
                        ]
                        
                  },
                                    {
                        "title":"SAR Requirements",  
                        "name" : "Vancomycin: Hover over compound to view areas.",
                        "imagePath" : "slide4-vancomycin.PNG",
                        "imgWidth" : 500,
                        "imgPadding" : 100,
                        "compoundHotspots" : [
                              {
                                    "name": "Peptide Bond",
                                    "y": 216,
                                    "x": 435,
                                    "size": 30,
                                    "color": "blue",
                                    "text": "Vancomycin contains many peptide bonds"
                              },
                               {
                                    "name": "H-Bond with D-Ala-D-Ala",
                                    "y": 233,
                                    "x": 410,
                                    "size": 20,
                                    "color": "red",
                                    "text": "This atom forms hydrogen bonds with D-Ala-D-Ala"
                              },
                              {
                                    "name": "H-Bond with D-Ala-D-Ala",
                                    "y": 320,
                                    "x": 394,
                                    "size": 20,
                                    "color": "red",
                                    "text": "This atom forms hydrogen bonds with D-Ala-D-Ala"
                              },
                               {
                                    "name": "H-Bond with D-Ala-D-Ala",
                                    "y": 386,
                                    "x": 387,
                                    "size": 20,
                                    "color": "red",
                                    "text": "This atom forms hydrogen bonds with D-Ala-D-Ala"
                              },
                              {
                                    "name": "H-Bond with D-Ala-D-Ala",
                                    "y": 544,
                                    "x": 306,
                                    "size": 20,
                                    "color": "red",
                                    "text": "This atom forms hydrogen bonds with D-Ala-D-Ala"
                              }
                        ]
                        
                  },
                  {
                        "title":"Practice Problem",  
                        "name" : "Mechanism of Action",
                        "imagePath" : "slide5-9.PNG",
                        "question" : "Which compound below interferes with peptide cross-linking?",
                        "options" : [
                              "Compound 1", 
                              "Compound 2", 
                              "Compound 3"
                        ],
                        "answer" : "Compound 3",
                        "explanation" : "Vancomycin (Compound 3) Binds directly to the D-Ala-D-Ala terminal to prevent peptide cross-linking."
                  },
                  {
                        "title":"Practice Problem",  
                        "name" : "Mechanism of Action",
                        "imagePath" : "slide6-7-8.PNG",
                        "question" : "Which compound below inhibits the conversion of UDP-NAG→ UDP-NAM?",
                        "options" : [
                              "Compound 1", 
                              "Compound 2", 
                              "Compound 3"
                        ],
                        "answer" : "Compound 2",
                        "explanation" : "Fosfomycin (Compound 2) Results in irreversible alkylation of the active cysteine on MurA."
                  },
                  {
                        "title":"Practice Problem",  
                        "name" : "Mechanism of Action",
                        "imagePath" : "slide6-7-8.PNG",
                        "question" : "Which compound below inhibits Ala racemase & D-Ala ligase?",
                        "options" : [
                              "Compound 1", 
                              "Compound 2", 
                              "Compound 3"
                        ],
                        "answer" : "Compound 3",
                        "explanation" : "Cycloserine (Compound 3) Prevents conversion of L-Ala→ D-Ala and the joining of D-Ala & D-Ala."
                  },
                  {
                        "title":"SAR Practice Problem",  
                        "name" : "Mechanism of Action",
                        "imagePath" : "slide6-7-8.PNG",
                        "question" : "Which compound below inhibits pyrophosphatase?",
                        "options" : [
                              "Compound 1", 
                              "Compound 2", 
                              "Compound 3"
                        ],
                        "answer" : "Compound 1",
                        "explanation" : "Bacitracin (Compound 1) Inhibits the recycling of bactoprene molecule."
                  },
                  {
                        "title":"SAR Practice Problem",  
                        "name" : "Clinical Case Study ",
                        "imagePath" : "slide5-9.PNG",
                        "question" : "GT is diagnosed with C. difficile. Which oral antibiotic would be best to treat his infection?",
                        "options" : [
                              "Compound 1", 
                              "Compound 2", 
                              "Compound 3"
                        ],
                        "answer" : "Compound 3",
                        "explanation" : "Vancomycin (Compound 3) is not orally absorbed, so it will stay in the gut to treat the infection in the large intestine"
                  },
                  {
                        "title":"SAR Practice Problem",  
                        "name" : "Clinical Case Study ",
                        "imagePath" : "slide10-11.PNG",
                        "question" : "SM is diagnosed with a UTI infection. Which compound would be best to treat his infection and has few side effects?",
                        "options" : [
                              "Compound 1", 
                              "Compound 2", 
                              "Compound 3"
                        ],
                        "answer" : "Compound 2",
                        "explanation" : "Fosfomycin (Compound 2) is indicated for urinary tract infections, and is especially active against E. Coli"
                  },
                  {
                        "title":"SAR Practice Problem",  
                        "name" : "Clinical Case Study ",
                        "imagePath" : "slide10-11.PNG",
                        "question" : "GT has a history of psychosis. Which antibiotic below is best avoided in this patient?",
                        "options" : [
                              "Compound 1", 
                              "Compound 2", 
                              "Compound 3"
                        ],
                        "answer" : "Compound 1",
                        "explanation" : "Cycloserine (Compound 1) acts as a partial agonist at the NMDA receptor can result in dose-dependent neurologic and psychiatric disturbances."
                  },
                  {
                        "title":"SAR Practice Problem",  
                        "name" : "Clinical Case Study ",
                        "imagePath" : "slide12-13.PNG",
                        "question" : "BK has kidney dysfunction. Which 2 antibiotics below have side effects that would be harmful to this patient?",
                        "options" : [
                              "Compound 1 & 2", 
                              "Compound 1 & 3", 
                              "Compound 2 & 3"
                        ],
                        "answer" : "Compound 1 & 3",
                        "explanation" : "Bacitracin (Compound 1) and vancomycin (Compound 3) can both result in nephrotoxicity."
                  },
                  {
                        "title":"SAR Practice Problem",  
                        "name" : "Clinical Case Study ",
                        "imagePath" : "slide12-13.PNG",
                        "question" : "AM’s bacterial infection is not responding to treatment. The bacteria in her body have become resistant to the antibiotic by producing D-Ala-D-Lac. Which of the antibiotics was she taking?",
                        "options" : [
                              "Compound 1", 
                              "Compound 2", 
                              "Compound 3"
                        ],
                        "answer" : "Compound 3",
                        "explanation" : "Vancomycin (Compound 3) normally binds to D-Ala-D-Ala of the pentapeptide tail, but with this change to D-Ala-D-Lac, it can no longer bind."
                  }
            ],
            "testItems":[
                  {
                        "title":"",  
                        "question" : "Gram positive bacteria have ___________ in their cell wall that determine its rigidity and __________ to regulate cation movement.",
                        "options" : [
                              "teichoic acid, peptidoglycan",
                              "cellulose, teichoic acid",
                              "peptidoglycan, porins",
                              "cellulose, porins", 
                              "peptidoglycan, teichoic acid"
                        ],
                        "answer" : "peptidoglycan, teichoic acid"
                  },
                  {
                        "title":"",  
                        "question" : "In Gram negative bacteria the area between the cytoplasmic membrane and thin layer of peptidoglycan is called the ___________.",
                        "options" : [
                              "pericardium space",
                              "endoplasmic space",
                              "periplasmic space",
                              "pleuraplasmic space"
                        ],
                        "answer" : "periplasmic space"
                  },
                  {
                        "title":"",  
                        "question" : "Source of acetate in N-acetyl glucosamine (NAG) is _________.",
                        "options" : [
                              "MurA",
                              "pyrophosphatase",
                              "phosphoenolpyruvate",
                              "acetyl CoA"
                        ],
                        "answer" : "acetyl CoA"
                  },
                  {
                        "title":"",  
                        "question" : "__________ is an irreversible inhibitor of MurA and targets the enzyme UDP-NAG Transferase",
                        "options" : [
                              "Cycloserin",
                              "Bactoprene",
                              "Fosfomycin",
                              "Nitrofurantoin"
                        ],
                        "answer" : "Fosfomycin"
                  },
                  {
                        "title":"",  
                        "question" : "Fosfomycin is indicated for ___________",
                        "options" : [
                              "meningitis",
                              "UTI",
                              "pneumonia",
                              "yeast infection"
                              
                        ],
                        "answer" : "UTI"
                  },
                  {
                        "title":"",  
                        "question" : "_____________ is a reversible competitive inhibitor of Alanine racemase and D-Ala D-Ala ligase",
                        "options" : [
                              "Fosfomycin",
                              "Bacitracin",
                              "Vancomycin",
                              "Cycloserine"
                        ],
                        "answer" : "Cycloserine"
                  },
                  {
                        "title":"",  
                        "question" : "A serious side effect of cycloserine is ____________ caused by NMDA binding",
                        "options" : [
                              "muscle aches",
                              "ototoxicity",
                              "nephrotoxicity",
                              "neurotoxicity"
                        ],
                        "answer" : "neurotoxicity"
                  },
                  {
                        "title":"",  
                        "question" : "_________ binds to pyrophosphatase and prevents regeneration of _________",
                        "options" : [
                              "Bactoprene, Bacitracin",
                              "Bacitracin, Bactoprene",
                              "Vancomycin, Acetyl coA",
                              "Cycloserine, Acetyl coA",
                              "Bacitracin, Peptidoglycan",
                              "Vancomycin, Peptidoglycan"
                        ],
                        "answer" : "Bacitracin, Bactoprene"
                  },
                  {
                        "title":"",  
                        "question" : "Vancomycin binds to peptidoglycan to prevent crosslinking. Resistance to Vancomycin occurs through a change in structure of peptidoglycan from an ___________.",
                        "options" : [
                              "ester, to an amide",
                              "amide to an ester",
                              "amine to an ester",
                              "amide to an ether",
                              "amide to an ether"
                        ],
                        "answer" : "amide to an ester"
                  },
                  {
                        "title":"",  
                        "question" : "Vancomycin is not orally absorbed but can treat ___________",
                        "options" : [
                              "Meningitis",
                              "UTI",
                              "C. Diff Infections",
                              "Pheumonia"
                        ],
                        "answer" : "C. Diff Infections"
                  },
                  {
                        "title":"",  
                        "question" : "To avoid the side effect ___________, vancomycin should be infused _________",
                        "options" : [
                              "Steven’s Johnson Syndrome, slowly",
                              "Reye’s Syndrome, rapidly",
                              "Red Man Syndrome, slowly",
                              "Extrapyramidal symptoms, rapidly"
                        ],
                        "answer" : "Red Man Syndrome, slowly"
                  },
                  {
                        "title":"",  
                        "question" : "Daptomycin cannot be used for ________ because of inactivation by surfactants",
                        "options" : [
                              "UTI",
                              "Pneumonia",
                              "Otitis",
                              "Sinusitis"
                        ],
                        "answer" : "Pneumonia"
                  }
            ],
             "reviewItems":[
                  {
                        "title": "Fosfomycin",  
                        "sections" : [
                              {"title": "Compound", "imagePath": "fosfomycin.PNG" },
                              {"title": "SAR", "content": "" },
                              {"title": "Type of Inhibitor", "content": ""},
                              {"title": "MOA & Target", "content": ""},
                              {"title": "MOR", "content": ""},
                              {"title": "Spectrum", "content": ""},
                              {"title": "Toxicities", "content": ""}
                        ]
                  },
                  {
                        "title": "Cycloserine",  
                        "sections" : [
                              {"title": "Compound", "imagePath": "cycloserine.PNG" },
                              {"title": "SAR", "content": "" },
                              {"title": "Type of Inhibitor", "content": ""},
                              {"title": "MOA & Target", "content": ""},
                              {"title": "MOR", "content": ""},
                              {"title": "Spectrum", "content": ""},
                              {"title": "Toxicities", "content": ""}
                        ]
                  },
                  {
                        "title": "Bacitracin",  
                        "sections" : [
                              {"title": "Compound", "imagePath": "bacitracin.PNG" },
                              {"title": "SAR", "content": "" },
                              {"title": "Type of Inhibitor", "content": ""},
                              {"title": "MOA & Target", "content": ""},
                              {"title": "MOR", "content": ""},
                              {"title": "Spectrum", "content": ""},
                              {"title": "Toxicities", "content": ""}
                        ]
                  },
                  {
                        "title": "Vancomycin",  
                        "sections" : [
                              {"title": "Compound", "imagePath": "vancomycin.PNG" },
                              {"title": "SAR", "content": "" },
                              {"title": "Type of Inhibitor", "content": ""},
                              {"title": "MOA & Target", "content": ""},
                              {"title": "MOR", "content": ""},
                              {"title": "Spectrum", "content": ""},
                              {"title": "Toxicities", "content": ""}
                        ]
                  }
            ],                     
            "exampleReview":[
                  {
                        "title": "Fosfomycin",  
                        "sections" : [
                              {"title": "Compound", "imagePath": "fosfomycin.PNG" },
                              {"title": "SAR", "content": "PEP mimic, Reactive epoxide group" },
                              {"title": "Type of Inhibitor", "content": "Irreversible inhibitor/Suicide inhibitor"},
                              {"title": "MOA & Target", "content": "MOA: Inhibits PEP which inhibits cell peptidoglycan synthesis - specifically NAM synthesis (Stage 1: Synthesis of Building Blocks) Bactericidal Target: UDP-NAG phosphoenoylpyruvuyl (PEP) transferase = MurA"},
                              {"title": "MOR", "content": "1) Mutation of active site (Microbe has Cysteine instead of Asp) 2) Mutation of glycerophosphate transporter"},
                              {"title": "Spectrum", "content": "Broad – both Gram positive and Gram negative"},
                              {"title": "Toxicities", "content": "Low Nausea, vomiting, diarrhea, hypersensitivity, skin rash"}
                        ]
                  },
                  {
                        "title": "Cycloserine",  
                        "sections" : [
                              {"title": "Compound", "imagePath": "cycloserine.PNG" },
                              {"title": "SAR", "content": "D-Ala analogue, 5-membered ring" },
                              {"title": "Type of Inhibitor", "content": "Non-covalent/competitive inhibitor – substrate mimic Binds 100x more tightly to the enzymes (rigid structure)"},
                              {"title": "MOA & Target", "content": "MOA; Competitive inhibitor of racemase Which inhibits cell peptidoglycan synthesis. (Stage 1: Synthesis of Building Blocks) Bactericidal Target: D-Ala-D-Ala racemase and D-Ala-D-Ala ligase"},
                              {"title": "MOR", "content": "Overexpression of  D-alanine racemase (AlrA)"},
                              {"title": "Spectrum", "content": "Broad – both Gram positive and Gram negative"},
                              {"title": "Toxicities", "content": "Neurotoxic CNS disturbance, anxiety, confusion and drowsiness"}
                        ]
                  },
                  {
                        "title": "Bacitracin",  
                        "sections" : [
                              {"title": "Compound", "imagePath": "bacitracin.PNG" },
                              {"title": "SAR", "content": "Large molecule with many peptide bonds" },
                              {"title": "Type of Inhibitor", "content": "N/A"},
                              {"title": "MOA & Target", "content": "MOA: Binds to pyrophosphatase in the presence of Magnesium,thus preventing regeneration of Bactoprene. It is more active if zinc is already present in the preparation, aiding in the binding to pyrophosphatase which inhibits cell peptidoglycan synthesis. (Stage 2: Synthesis of Membrane-bound Precursors and Polymerization) Bactericidal Target: Pyrophosphatases"},
                              {"title": "MOR", "content": "Failure to penetrate membrane"},
                              {"title": "Spectrum", "content": "Gram positive only – too big to get through outer membrane of Gram negative"},
                              {"title": "Toxicities", "content": "Nephrotoxicity – not used systemically*/topical"}
                        ]
                  },
                  {
                        "title": "Vancomycin",  
                        "sections" : [
                              {"title": "Compound", "imagePath": "vancomycin.PNG" },
                              {"title": "SAR", "content": "Large molecule with many peptide bonds - Circled atoms form hydrogen bonds with D-Ala-D-Ala" },
                              {"title": "Type of Inhibitor", "content": "Competitive/Reversible"},
                              {"title": "MOA & Target", "content": "(Stage 2: Synthesis of Membrane-bound Precursors and Polymerization) Binds directly to the D-Ala-D-Ala terminal to prevent peptide cross-linking Bactericidal Target:  D-Ala-D-Ala"},
                              {"title": "MOR", "content": "1. Alter the substrate – make D-Ala-D-Lac. Results in loss of H-bond between vancomycin and dipeptide. 2.  Thicker cell wall of bacterium"},
                              {"title": "Spectrum", "content": " Gram positive only"},
                              {"title": "Toxicities", "content": "Redman syndrome (if infused too quickly), Nephrotoxicity, Hearing loss, Rash"}
                        ]
                  }
            ]            
      },
      {
            "id": 10,
            "name": "Beta-Lactams",
            "learnItems":[
                  {
                        "title":"SAR Requirements",  
                        "name" : "Penicillin: Hover over compound to view areas.",
                        "imagePath" : "slide2-penicillin.PNG",
                        "imgWidth" : 500,
                        "imgPadding" : 150,
                        "compoundHotspots" : [
                              {
                                    "name": "β-Lactam Ring",
                                    "y": 287,
                                    "x": 400,
                                    "size": 40,
                                    "color": "black",
                                    "text": "β-Lactam Ring & Fused Bicyclic System: Creates a strained system (but less strain than the penicillins, so less reactive)"
                              },
                              {
                                    "name": "Position 1",
                                    "y": 340,
                                    "x": 437,
                                    "size": 35,
                                    "color": "green",
                                    "text": "Must be a nitrogen"
                              },
                              {
                                    "name": "Position 2",
                                    "y": 423,
                                    "x": 550,
                                    "size": 90,
                                    "color": "blue",
                                    "text": "Must be a carboxylic acid for activity; binds to charged nitrogen of a lysine residue in the binding site"
                              },
                              {
                                    "name": "Position 3",
                                    "y": 280,
                                    "x": 588,
                                    "size": 55,
                                    "color": "darkorange",
                                    "text": "Any change will lower activity"
                              },
                              {
                                    "name": "Position 4",
                                    "y": 209,
                                    "x": 512,
                                    "size": 45,
                                    "color": "purple",
                                    "text": "Sulfur is usual, but not essential"
                              },
                              {
                                    "name": "Position 5",
                                    "y": 192,
                                    "x": 397,
                                    "size": 70,
                                    "color": "deeppink",
                                    "text": "No substitutions allowed; cis stereochemistry with hydrogens at position 5 & 6 is essential"
                              },
                              {
                                    "name": "R Group",
                                    "y": 215,
                                    "x": 182,
                                    "size": 40,
                                    "color": "grey",
                                    "text": "EWG: increases the acid stability of the compound. Bulky group: directly attached to the amide will make the compound more B-lactamase resistant. Polar group: broadens the spectrum as this allows the compound to pass through the porins of gram negative bacteria"
                              },
                              {
                                    "name": "Position 7",
                                    "y": 360,
                                    "x": 333,
                                    "size": 60,
                                    "color": "red",
                                    "text": "Must be a carbonyl"
                              }
                        ]
                        
                  },
                  {
                        "title":"SAR Requirements",  
                        "name" : "Cephalosporin: Hover over compound to view areas.",
                        "imagePath" : "slide4-cephalosporin.PNG",
                        "imgWidth" : 500,
                        "imgPadding" : 150,
                        "compoundHotspots" : [
                              {
                                    "name": "β-Lactam Ring",
                                    "y": 271,
                                    "x": 404,
                                    "size": 35,
                                    "color": "black",
                                    "text": "β-Lactam Ring & Fused Bicyclic System: Creates a strained system (but less strain than the penicillins, so less reactive)"
                              },
                              {
                                    "name": "Position 1",
                                    "y": 320,
                                    "x": 438,
                                    "size": 35,
                                    "color": "green",
                                    "text": "Must be a nitrogen"
                              },
                              {
                                    "name": "Position 2",
                                    "y": 403,
                                    "x": 516,
                                    "size": 70,
                                    "color": "blue",
                                    "text": "Must be a carboxylic acid for activity; binds to charged nitrogen of a lysine residue in the binding site"
                              },
                              {
                                    "name": "Position 3",
                                    "y": 319,
                                    "x": 604,
                                    "size": 70,
                                    "color": "darkorange",
                                    "text": "R2 Group: Non-metabolized group: increases oral activity & acid stability. MTT group: extended spectrum, longer-half life, higher potency. Pyrimidine ring (positive charge): forms a zwitterion & increases solubility. 1,3 thiazole ring: Anti-MRSA activity"
                              },
                              {
                                    "name": "Position 5",
                                    "y": 185,
                                    "x": 497,
                                    "size": 38,
                                    "color": "purple",
                                    "text": "Sulfur is usual, but not essential"
                              },
                              {
                                    "name": "Position 6",
                                    "y": 200,
                                    "x": 437,
                                    "size": 45,
                                    "color": "deeppink",
                                    "text": "No substitutions allowed"
                              },
                              {
                                    "name": "R1 Group",
                                    "y": 215,
                                    "x": 182,
                                    "size": 40,
                                    "color": "grey",
                                    "text": "EWG: increases the acid stability of the compound. Bulky group: directly attached to the amide will make the compound more B-lactamase resistant. Polar group: broadens the spectrum as this allows the compound to pass through the porins of gram negative bacteria. Oxime: increases B-lactamase resistance."
                              },
                              {
                                    "name": "Position 7",
                                    "y": 195,
                                    "x": 369,
                                    "size": 45,
                                    "color": "brown",
                                    "text": "R3 group: Addition of OCH3 (7-alpha-methoxy) increases B-lactamase resistance"
                              },
                              {
                                    "name": "Position 8",
                                    "y": 353,
                                    "x": 340,
                                    "size": 60,
                                    "color": "red",
                                    "text": "Must be a carbonyl"
                              }
                        ]
                        
                  },
                  {
                        "title":"SAR Requirements",  
                        "name" : "Cephalosporin / Ceftaroline: Hover over compound to view areas.",
                        "imagePath" : "ceftaroline.PNG",
                        "imgWidth" : 500,
                        "imgPadding" : 150,
                        "compoundHotspots" : [
                              {
                                    "name": "",
                                    "y": 169,
                                    "x": 136,
                                    "size": 50,
                                    "color": "orangered",
                                    "text": "Info: Specific requirements for Ceftaroline (5th generation) to be aware of"
                              }
                        ]
                        
                  },
                  {
                        "title":"Other β-lactam Classes",  
                        "name" : "Carbapenems: Hover over Imipenem to view areas.",
                        "imagePath" : "imipenem.PNG",
                        "imgWidth" : 500,
                        "imgPadding" : 150,
                        "compoundHotspots" : [
                              {
                                    "name": "",
                                    "y": 286,
                                    "x": 340,
                                    "size": 85,
                                    "color": "orangered",
                                    "text": "Unsaturated 5-membered ring connected to the β-lactam ring"
                              }
                        ]
                        
                  },
                  {
                        "title":"Other β-lactam Classes",  
                        "name" : "Monobactams: Hover over Aztreonam to view areas.",
                        "imagePath" : "aztreonam.PNG",
                        "imgWidth" : 400,
                        "imgPadding" : 150,
                        "compoundHotspots" : [
                              {
                                    "name": "",
                                    "y": 317,
                                    "x": 442,
                                    "size": 50,
                                    "color": "orangered",
                                    "text": "Only a single B-lactam ring"
                              }
                        ]
                        
                  },
                  {
                        "title":"β-lactamase Inhibitors",  
                        "name" : "Hover over each molecule to view names.",
                        "imagePath" : "aztreonam.PNG",
                        "imgWidth" : 400,
                        "imgPadding" : 150,
                        "compoundHotspots" : [
                              {
                                    "name": "",
                                    "y": 317,
                                    "x": 442,
                                    "size": 50,
                                    "color": "orangered",
                                    "text": "Only a single B-lactam ring"
                              }
                        ]
                        
                  }
            ],
            "testItems":[
                  {
                        "title":"",  
                        "question" : "Penicillins bind and inhibit __________ to prevent crosslinking.",
                        "options" : [
                              "Ligases",
                              "Mur A",
                              "Pyrophosphatases",
                              "Penicillin Binding Proteins (PBP)"
                        ],
                        "answer" : "Penicillin Binding Proteins (PBP)"
                  },
                  {
                        "title":"",  
                        "question" : "Resistance to penicillins develops quickly due to ________ or PBP mutations",
                        "options" : [
                              "β-lactamases",
                              "acid-base condition changes",
                              "alteration of side chains"
                        ],
                        "answer" : "β-lactamases"
                  },
                  {
                        "title":"",  
                        "question" : "Clavulanic acid, Sulbactam, and Tazobactam are all examples of β-lactamase ________.",
                        "options" : [
                              "inducers",
                              "inhibitors",
                              "producers"
                        ],
                        "answer" : "inhibitors"
                  },
                  {
                        "title":"",  
                        "question" : "_________ is combined with imipenem to avoid degradation in the kidney.",
                        "options" : [
                              "Polymixin",
                              "Colistin",
                              "Cilastatin",
                              "Clavulanic acid "
                        ],
                        "answer" : "Cilastatin"
                  },
                  {
                        "title":"",  
                        "question" : "Carbapenem resistant Enterobacteriaceae (CRE) can be treated with polymixin and ______. ",
                        "options" : [
                              "cilastatin",
                              "clavulanic acid",
                              "sulbactam",
                              "colistin"
                        ],
                        "answer" : "colistin"
                  },
                  {
                        "title":"",  
                        "question" : "Carbapenems cannot be combined with _________. ",
                        "options" : [
                              "tetracyclines",
                              "other beta lactams",
                              "aminoglycosides",
                              "macrolides"
                        ],
                        "answer" : "aminoglycosides"
                  },
                  {
                        "title":"",  
                        "question" : "Cephalosporins are inherently ____ active than Penicillins but are ____ resistant to β-lactamases.",
                        "options" : [
                              "less, more",
                              "more, less",
                              "more, not"
                        ],
                        "answer" : "less, more"
                  },
                  {
                        "title":"",  
                        "question" : "Cephalosporins substituted with a _______ can extend the spectrum but also cause side effects such as _______ and Disulfiram-like effect.",
                        "options" : [
                              "amide, hemolytic anemia",
                              "ester, thrombocytosis",
                              "sulfa group, leukopenia",
                              "MTT group, hypothrombocytopenia"
                        ],
                        "answer" : "MTT group, hypothrombocytopenia"
                  },
                  {
                        "title":"",  
                        "question" : "_______ are mostly reserved for serious Gram-negative infections such as meningitis.",
                        "options" : [
                              "Carbapenems",
                              "Beta Lactams",
                              "Aminoglycosides",
                              "Monobactams"
                        ],
                        "answer" : "Monobactams"
                  },
                  {
                        "title":"",  
                        "question" : "_______ is an inhalent to treat chronic pseudomonas infections with CF patients, has activity against pseudomonas because it has the same side chain as _______.",
                        "options" : [
                              "Imipenem, cefixime",
                              "Meropenem, ceftaxime",
                              "Aztreonam, ceftazidine",
                              "Ertapenem, cephalexin"
                        ],
                        "answer" : "Aztreonam, ceftazidine"
                  }
            ],
             "reviewItems":[
                   {
                        "title": "Penicillins",  
                        "sections" : [
                              {"title": "Compound", "imagePath": "penicillins.PNG" },
                              {"title": "SAR", "content": ""},
                              {"title": "Target", "content": ""},
                              {"title": "MOA", "content": ""},
                              {"title": "MOR", "content": ""},
                              {"title": "Spectrum", "content": ""},
                              {"title": "Type of Inhibitor", "content": ""},
                              {"title": "Toxicities", "content": ""}
                        ]
                  },
                  {
                        "title": "Cephalosporins",  
                        "sections" : [
                              {"title": "Compound", "imagePath": "cephalosporins.PNG" },
                              {"title": "SAR", "content": ""},
                              {"title": "Target", "content": ""},
                              {"title": "MOA", "content": ""},
                              {"title": "MOR", "content": ""},
                              {"title": "Spectrum", "content": ""},
                              {"title": "Type of Inhibitor", "content": ""},
                              {"title": "Toxicities", "content": ""}
                        ]
                  },
                  {
                        "title": "Monobactam",  
                        "sections" : [
                              {"title": "Compound", "imagePath": "monobactam.PNG" },
                              {"title": "SAR", "content": ""},
                              {"title": "Target", "content": ""},
                              {"title": "MOA", "content": ""},
                              {"title": "MOR", "content": ""},
                              {"title": "Spectrum", "content": ""},
                              {"title": "Type of Inhibitor", "content": ""},
                              {"title": "Toxicities", "content": ""}
                        ]
                  },
                  {
                        "title": "Carbapenem",  
                        "sections" : [
                              {"title": "Compound", "imagePath": "carbapenem.PNG" },
                              {"title": "SAR", "content": ""},
                              {"title": "Target", "content": ""},
                              {"title": "MOA", "content": ""},
                              {"title": "MOR", "content": ""},
                              {"title": "Spectrum", "content": ""},
                              {"title": "Type of Inhibitor", "content": ""},
                              {"title": "Toxicities", "content": ""}
                        ]
                  },
                  {
                        "title": "Beta Lactamase Inhibitor",  
                        "sections" : [
                              {"title": "Compound", "imagePath": "BetaLactamaseInhibitor.PNG" },
                              {"title": "SAR", "content": ""},
                              {"title": "Target", "content": ""},
                              {"title": "MOA", "content": ""},
                              {"title": "MOR", "content": ""},
                              {"title": "Spectrum", "content": ""},
                              {"title": "Type of Inhibitor", "content": ""},
                              {"title": "Toxicities", "content": ""}
                        ]
                  }
            ],      
            "exampleReview":[
                  
            ]            
      }
]